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Abstract
The bacteriophage K-derived peptidase CHAPk (Cysteine/Histidine-dependant
amidohydrolase peptidase) can be produced from E. coli XL 1-Blue. Standard
operating procedures for the producion, purification and quality assessment of the
peptidase were developed and set out in detail in this thesis. CHAPk exhibits strong
antistaphylococcal properties and the purified enzyme was evaluated for its potential
to eliminate S. aureus from the bovine udder and from human skin. As a teat dip
CHAPk reduced the levels of S. aureus by three to five log cycles on both animal and
human surfaces. CHAPk activity in milk was evaluated using challenge assays against
the bovine mastitis isolate S. aureus DPC5246. The enzyme was found to eliminate
cells in 10% resconstituted skim milk, however, its antistaphylococcal activity in raw
milk was not as good. Given that in nature, many bacterial cells are not necessarily in
the exponential phase of growth, activity of CHAPk against stationary-phase S.
aureus was also evaluated. Activity on stationary-phase cells was evaluated over a
period of 5 weeks using three S. aureus strains, DPC5246, Newbould 305 and Xen 29
and it was revealed that when aged at 30°C, cultures older than 3 days could be up to
2-fold less sensitive to the endolysin; there was less of a difference when cells were
aged at 4°C. Finally, it was found that the process of lyophilization consistently
reduced the concentration and activity of the CHAPk enzyme regardless of storage
conditions of the powder.

CHAPTER 1

Literature review

CONTENTS

Section 1

Introduction

Section 2
Section 2.1

Endolysin mode of action
Holins

Section 3
Section 3.1
Section 3.2
Section 3.3

Structure of endolysins
Lysins specific to Staphylococcus aureus
Lysins specific to Streptococci
Lysins specific to Bacillus anthracis

12
13
15
15

Section 4
Section 4.1
Section 4.2
Section 4.3

Endolysins as antibacterials
Mucous membranes
Endolysins in diagnostics
Applications in the food industry

17
18
20
20

Section 5

Engineering of endolysins

23

Section 6

Endolysins in synergy with other antimicrobials

25

Section 7
Section 7.1
Section 7.2

Resistance to endolysins
Gram-negative baeteria
Biofilms

28
28
29

Section 8

Safety and immunogenicity

30

Conclusion

32

References

33

1. Introduction

There is an increasing worldwide prevalence of antibiotic resistance among
pathogenic bacteria that is aggravated even further by the current decline in the
development of new antibiotics. Therefore, to meet these demands two possible
classes of novel antibacterials are bacteriophages (phages) and bacteriophage-encoded
enzymes such as endolysins (lysins). Phages are the most abundant entities on earth.
They are found wherever their hosts live and can be classified as either virulent or
tem.perate. Phages, like all viruses, are absolute parasites in that they do not have the
ability to make their own proteins. Therefore, to produce their progeny, phages must
infect a bacterial host and when they cannot find an appropriate host, many phages
maintain their ability to infect for decades, unless damaged by external agents
(Guttman et al. 2005). Virulent phages multiply using the lytic cycle. These phages
bind to the surface of their host cell and inject their genome. Most of the host
metabolism is taken over and becomes involved with making progeny phages.
Temperate phages, upon entering their host, can choose between either the lytic cycle
or the lysogenic cycle. With the lysogenic cycle the phage genome integrates with the
genome of the host but is sometimes maintained as a plasmid. After replication inside
their host, phages will need to find a means of releasing their progeny (Fischetti,
2010). Newly assembled phages using the lysogenic cycle can be continuously
released without killing the bacterial cells themselves (Russell, 1997). However, in
the case of bacteriophages using the lytic cycle, lysis of the host cell must be induced.
Phages that have small genomes of single stranded DNA or RNA damage the cell
wall of their host by producing a single protein that can inhibit peptidoglycan
synthesis. For phages with larger double stranded genomes, endolysins (which cleave

peptidoglycan) are produced (Borysowski et al. 2006).These murein hydrolases are
highly diverse and can be characterised by their ability to attack and destroy the cell
wall (Fischetti, 2006).

Fig 1: The lytic and lysogenic hacteriophage life cycles.

Previously whole phages have been exploited for the treatment or prophylaxis of
bacterial infectious diseases (Matsuzaki et al. 2005), and now lytic enzymes are being
5

used for bacterial control. In view of the rising numbers of antibiotic resistant
bacteria, studies have established that endolysins represent a very promising
alternative class of antibacterial for use against systematic infections. Endolysins have
the ability to eliminate bacteria with a low probability of bacterial resistance
developing (Kusuma et al. 2007). The objective of this chapter is to discuss the
features of endolysins and their potential applications.

2. Endolysin mode of action

Murein hydrolases can be sorted into two separate categories of enzyme. The first
category includes the autolysins which degrade peptidoglycan at specific sites during
the physiological growth of the bacterial cell. These enzymes are secreted from the
bacterial cytoplasm by N-tenninal signal peptides. The second category of murein
hydrolases are endolysins (Navarre et al. 1999). Endolysins are synthesised in phageinfected cells during the tenninal stage of the phage reproduction cycle (Loessner,
2005) and their main mode of action is the cleavage of the covalent bonds that are
present in the peptidoglycan. Peptidoglycan is a major component of the cell wall that
consists of sugars and amino acids and protects bacteria from rupture in environments
of low osmolarity. The sugar component of peptidoglycan consists of alternating
residues of p-1,4 linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid
(MurNAc) and the amino component is a chain of three to five amino acids that attach
to the MurNAc. The peptide chains cross-link with each other forming a rigid
network. When endolysins cleave specific bonds in the peptidoglycan, the result is the
lysis and subsequent death of the cell (Fhschetti, 2003). Based on the cleaving
specificity of the endolysins, they can be organized into four classes:
(a) N-acetylmuramidases (lysozymes, also called muramidases), (b) N-acetyl-(3-Dglueosaminidases (glycosidases), (c) N-acetylmuramoyl-L-alanine amidases, and (d)
L-alanoyl-D-glutamate endopeptidases.

Lysozymes (muramidases) cleave the glycan on the reducing side of MurNAc. These
are found in autolysins and phage lysins, for example the streptococcal phage lysin
B30 and the pneumococcal endolysin Cpl-1 (Nelson et al. 2012).
7

Fig 2: The cleavage sites of peptidoglycan hy the major endolysins classes are shown with
numbers: I, N-acetylmiirarnidases and transglyeosylase; 2, N-acetyl-f-D-glucosaminidases;
3, N-acetylmuramoyl-L-alanine amidases; 4 endopeptidase and 5, endopeptidase.
(Borysowski et al. 2006).

Glycosidases cleave the glyean of the peptidoglyean on the redueing side of GleNAe.
This aetivity is usually found in autolyins with the exeeption of the streptoeoceal
endolysin LanbdaSa2 (Pritehard et al. 2007). N-acetylmuramoyl-L-alanine amidases
eleave an amide bond between the MurNAc and L-alanine and this activity is very
common in phage endolysins. The endopeptidases eleave the peptide bonds between
two amino acids. Another elass of endolysin is the transglyeosylase, whieh do not
require water for the cleavage of the peptidoglycan. With the exception of
transglycosylases, all endolysins are hydrolases (Borysowski, 2006). Of all the
endolysins reported so far, amidases and muramidases are the most numerous

(Loessner, 2005). Due to the high osmotie pressure inside a baeterial eell eompared to
that of its external environment, the degrading of the peptidoglyean will result in the
extrusion of the eytoplasmie membrane and hypotonie lysis (Fisehetti, 2006).

2.1 Holins

During phage development in the infeeted baeteria, folded endolysin moleeules
aeeumulate in the eytosol (Wang et al. 2000). At this point they have no aeeess to the
peptidoglyean, and are thus harmless to the eell. Lysins, do not have signal peptide
sequenees (Loessner, 1997). Exeeptions are the lysins Lys44 from Oenoeoeeus
oeniphage fOp44 (Sao-Jose et al. 2000), and the lysin from Lactobacillus plantanim
phage Ogle, whieh show a seeretory signal at the N-temiinus (Kakikawa, 2002). For
all other lysins, aeeess to peptidoglyean from inside the eell is dependant on a protein
ealled a holin. Holins enable the endolysins to eross the inner membranes and are
elassified as Class 1 holins if they have three transmembrane domains (TMD) or elass
II holins if they have two TMD (Young, 2002). Class III holins have a single
transmembrane domain and a large hydrophilie periplasmie C-terminal tail that is
required for lysis inhibition (Ramaneulov and Young, 2001). Within each class, there
are some holins capable of acting on Gram-positive bacteria, and others that exert
their action on Gram-negative bacteria. At a genetically detemiined moment, holin
molecules gather in the cytosol forming patches, which result in membrane disruption
and endolysins can start to pass through the membrane lesions (Wang et al. 2003). In
this way, it can be said that the timing of lysis is controlled by holins. Both endolysin
and holin are essential for lysis. (Borysowski ct al. 2006). Typically the genes

encoding lysis proteins are clustered to fonn a lysis cassette, in which the holin gene
is located immediately upstream of the endolysin gene (Young, 2000).
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Fig .?.• Holin molecules gather and form lesions in the cytoplasmic membrane. These lesions
act as pores for the endolysins to pass through. It is now possible for the lysins to degrade the
peptidoglycan (Garcia et al. 2010).

While the main mode of antibacterial activity of lysins is based on the enzymatic
cleavage of peptidoglycan, some lysins in particular those from phages of Gram
negative bacteria affect bacterial cells by a different mechanism of activity. The
Bacillus amyloliquefaciens phage endolysin has been found to contain C-terminus
sequences that are similar to those found in cationic antimicrobial peptides (Orito et
al. 2004). This endolysin folds into a structure, made of a hydrophobic domain and a
hydrophilic domain, which allows it to interact with the negatively charged surface
lipopolysaccharides of the bacteria (Orito et al. 2004).

Another feature of lysins is their narrow antibacterial range when acting on the
bacterial cells from outside. Usually this is limited to the host bacterial species of the
0

phage that produced the lysin; however, lysins are capable of lysing most strains
within that bacterial species (Fischetti, 2008). For instance, the cndolysin Pal which is
encoded by the Streptococcus pneumoniae phage Dp-1 is capable of lysing 15
pneumococcal strains (Loeffler et al. 2001). Despite the fact that endolysins are
designed to work from inside the cells, they can act as exolysins when applied
exogenously to Gram-positive bacteria and only minute quantities of these enzymes
are required to bring about rapid cell lysis (Loessner ct al. 1995).

3. Structure of endolysins

For billions of years, both phages and bacteria have been evolving together and thus
share a common ancestry (Fischetti, 2011). There is a large amount of evidence to
support this and for some organisms; it is obvious that the host and lysins have co
evolved by exchanging their functional domains (Hermoso et al. 2007). The
endolysins from the DNA phages that have Gram-positive hosts are typically between
25 and 40 kDa in size. An exception is the streptococci lysin PlyC, which is 114 kDa
(Fischetti, 2011). A general feature of endolysins is that they are composed of
different polypeptide modules and these usually have two domains, each with very
distinct functions. It should be noted though that not every lysin has a modular
structure. For example, the T7 lysozyme has been shown to possess a single domain
and a globular structure (Cheng ct al. 1994). With no exceptions, the N-terminal
domain harbors the catalytic region of the lysin. This domain can consist of
glycosidases which hydrolyse the amino-sugar moities and amidases and peptidases
which break the peptide bonds of the peptidoglycan (Loessner, 2005).The majority of
endolysins have only one kind of muralytic activity, however some lysins, in
particular those that infect staphylococci, may contain more than one catalytic domain
(Navarre et al. 1999).

The binding between a lysin and the bacterial cell wall does not occur randomly but
takes place via the C-tenninal (Jado et al. 2003). The C-temiinal contains the cell wall
binding domain and this is very substrate specific (Loessner, 2005). For efficient
cleavage, the binding domain must bind to its cell wall substrate, which is usually a
carbohydrate. As these substrates are specific to the host bacteria, endolysins can be
12

considered as being highly selective. It is stated that endolysins bind at an affinity of
an immunoglobulin molecule and are single-use enzymes that require multiple
molecules to accomplish digestion of the cell wall (Loessner, 2002). An explanation
as to why these enzymes have evolved this way is that after lysis, the tight binding to
the wall substrate will control the diffusion of enzyme moleeules, preventing lysis of
potential phage hosts nearby (Loessner, 2002). For many endolysins, both the
catalytic and cell wall binding domains are required for activity but it has also been
shown in many studies that the C-tenninal is not always required for catalytie activity.
In the case of some lysins, both the catalytic and the cell wall-binding domain are
indispensable (Borysowski and Gorski, 20()0a). Truncated endolysins were reported
to display a higher antibacterial activity after their C-tenninal domains had been
removed, and this may indicate that for some endolysins the C terminal domain may
inhibit the N tenninal when not bound to the cognate cell wall (Morgan et al. 2009).

3.1 Lysins specific io Staphylococcus aureus:

Staphylococcus aureus is a challenging bacterial pathogen due to its growing
antibiotic resistance (Fenton et al. 2011). S. aureus specific endolysins cleave
covalent bonds in the peptidoglycan of both coagulase-positive and coagulasenegative staphylococci.

LysK is a lysin derived from the staphylococcal phage K (O’Flaherty et al. 2005).
This lysin has a modular structure with two catalytic domains, a CHAP (cysteine- and
histidine-dependent amidohydrolase/peptidase) domain and a central amidase-2
domain (A-acetylmuramoyl-l-alanine amidase), as well as a C-terminal SH3b cell-
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binding domain (Horgan et ai 2008). The antibacterial range of this enzyme is
restricted to S. aureus and coagulase-negative staphylococci. When truncated to just
its CHAP domain, the enzyme activity is two fold higher than the whole enzyme.

Phill bacteriophage endolysin has two peptidoglycan hydrolase activities: an Ntemiinal CHAP domain and an amidase domain. It also contains a C-terminal cell
wall-binding SH3b domain. For optimal lytic activity all modules are required
(Donovan et al. 2006). The lysin is capable of eliminating the biofilm of S. aureus on
artificial surfaces (Sass and Bierbaum, 2007). In a turbidity reduction assay, this
enzyme was found to have activity against several major staphylococcal mastitis
pathogens, including both S. aureus and coagulase-negative staphylococci.

MV-L is a lysin encoded by 5'. aureus phage phiMRll (Rashel et al. 2007). A
cysteine,

histidine-dependent

aminohydrolases/peptidases

(CHAP)

domain

(endopeptidase) and a Ami-2 domain (amidase). In vitro, MV-L rapidly lysed nine
methicillin-resistant S. aureus (MRSA) strains and a lysostaphin-resistant methicillinsusceptible S. aureus (MSSA) strain. These strains were isolated from different
countries. Under growing conditions, MV-L lysed two vancomycin-resistant S. aureus
(VRSA) strains and seven vancomycin-intermediate S. aureus (VISA) strains. Only
under non-growing conditions could eleven other VISA strains could be lysed .

LysH5 is a lysin derived from S. aureus bacteriophage Phi H5 (Obeso et al. 2008).
This enzyme contains three putative domains: an N-terminal CHAP domain, an
amidase domain situated in the central part of the protein, and a C-terminal cell wall
binding SH3b domain. It was found in turbidity reduction assays, that 52 S. aureus
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strains tested of both bovine and human origin were susceptible to LysH5 (Obeso et
al. 2008).

3.2 Lysins specific to Streptococci:

The endolysin PlyC has been found to be active against Lancefields’ groups A, C and
E streptococci however it is most active against group A streptococci such as
Streptococcus, pyogenes. S. pyogenes is a cause of both pharyngitis and rheumatic
fever (Nelson et a/. 2001). PlyC is the first lysin specific to S. pyogenes that was
evaluated as a potential antibacterial agent (Nelson et al. 2001). This lysin is an
amidase derived from group C streptococci C1 phage.

Streptococcus pneumoniae is a common colonizing bacterium in the respiratory tract
and is a cause of sinusitis, community-acquired pneumonia, bacteremia, and
meningitis (Jacobs, 2004). Pal and Cpl-1 are being developed as anti-pneumococcal
agents. Pal is an amidase, encoded by the pneumococcal bacteriophage Dp-1 (Loeffler
et al. 2001) and Cpl-1 is a muramidase of the Cp-1 phage (Loeffler et al. 2003). These
lysins have been used successfully in pre-clinical trials in the elimination of
antibiotic-resistant S. pneumoniae (Fenton et al. 2010).

3.3 Lysins specific to Bacillus anthracis:

Bacillus anthracis is classified as a category A biological weapon with the capacity of
developing multi-drug resistance (Yoong et al. 2006). PlyG and PlyPH are two
endolysins with activity against B. anthracis.
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PlyG is a putative amidase, encoded by B. anthracis y phage (Schuch et al. 2002). Out
of the 14 isolates of B. anthracis that were tested, PlyG could lyse all of them and one
strain of Bacillus cereus (closely related to B. anthracis).

PlyPH is a lytic enzyme that is of putative bacteriophage origin. This enzyme is lytic
against B. anthracis and was shown to remain active over the wide range of pH values
4.5 and 10.5 (Yoong et al. 2006).

4. Endoiysins as antibacterials

Bacterial antibiotic resistance can be acquired as a result of horizontal gene transfer
between baeteria with a lag phase before resistance and then exponential growth of
resistant bacteria (Austin and Anderson, 1999). Instead, research on the development
of new antibioties has been decreasing (Talbot et al. 2006). Current types of
antibiotics include penicillins, cephalosporins, fluoroquinolones and tetracyclines. As
phages are one of the most abundant biology entities on Earth, the use of their
endoiysins provides a rich and natural supply of antibacterials. Endoiysins being
peptidoglycan specific and genus specific, have a narrow antibacterial spectrum and
thus won’t disturb any other natually occuring mierotlora (Borysowski ct al. 2006). It
is possible that in the future purified phage endoiysins might be used therapeutically
for removing the food and animal pathogens that cause illness, fatalities and result in
worldwide economic losses.

Use of these enzymes would also be beneficial in

controlling the levels of pathogenic bacteria in environments sueh as hospitals.
Endolysin trials have been shown to remove a variety of bacteria ineluding
Enterococci strains, B. anthracis, Clostridium difficile, antibiotic resistant S.
pneumoniae, S. aureus and MRSA. To date scientific literature has shown that
endoiysins are highly efficient at eliminating infeetious bacteria in animal models.
The ability of endoiysins to kill bacteria was first reported in 1959. In 2001, it was
shown that reeombinant endoiysins might be successfully used as antimicrobial agents
(Nelson et al. 2001). A possible reason for the delay in the study of endoiysins as
antimicrobial agents is that until reeently the problem of antibiotie resistance was not
considered serious enough (Borysowski et al. 2006). The first application of lytic
enzymes may be the prophylaxis of staphyloeoceal infections by using endoiysins to
17

coat the surfaces of catheters and implants and thus preventing colonization. Other
applications include the elimination of bacteria in mucous membranes, the treatment
of bacterial infections, the biocontrol of bacteria in food and the protection of plants.
One of the first attempts at studying the effect of endolysins on bacterial infections
was with the B. anthracis phage y PlyG amidase. It was shown that the lysin was
capable of degrading the peptidoglycan of 14 B. anthracis isolates and a single strain
of B. cereus (Schuch et al. 2002).

4.1 Mucous membranes

fhe human mucous membranes are the reservoirs for many of the pathogenic bacteria
found in the environment (Borysowski et al. 2006). This is a reason why most human
infections begin at a mucous membrane site. Specific lysins that are able to kill Gram
positive bacteria rapidly after contact have now been identified and purified (Fischetti,
2008). For instance, a single treatment with the endolysin CHAPk brought about a
two-log reduction in S. aureus Xen29 cells in one hour from the nasal mucosa of mice
(Fenton et al. 2010). In addition, endolysins were also shown to be highly effective in
killing bacteria colonizing mucous membranes in other experimental models of
colonization. The Cl phage endolysin was the first lysin to be used as a topical
antibacterial agent. This endolysin comes from the group C streptococci Cl phage.
Interestingly, in spite of the endolysin being from a group C phage, this enzyme was
found to be most active against group A streptococci (Nelson et al. 2001). This lysin
works very rapidly and in this study, three in vivo experiments with mice were carried
out. The first experiment found that after 24 hours, none of the mice treated with 1000
units of the Cl phage endolysin were colonized with the group A streptococci that had

been given orally and nasally to the mice. In the second experiment it was clear that
the lysin provided protection From colonization, and in the third experiment when 500
units of enzyme was given to heavily colonized mice none of the streptococci was
detected after two hours. Despite the number of positive cultures increasing after 48
hours, this experiment showed that with periodic treatment, the streptococci might be
eliminated (Nelson et al. 2001). The Pal amidase from the phage Dp-1 was shown to
lyse 15 strains of S. pneumoniae, nine of which are resistant to penicillin and
frequently cause disease (Sheehan et al. 1997). It was also found that one topical dose
of Pal could clear bacteria from mucosa in a murine sepsis model (Loeffler et al.
2001). The muramidase Cpl-1 has a common binding domain as Pal. It was found that
five hours after intravenous and oral treatment with 1000 pg of Cpl-1, no pneunococci
were recovered in the nasal wash (Loeffler et al. 2003).

PlyGBS is a recombinant streptococcal lysin that has been developed, to prevent
Streptoeoeeus agalactiae infection in newborns. This enzyme is active against group
A, B, C, G and L streptococci. S. agalactiae colonises the human lower
gastrointestinal tract and genitals. Therefore, there is a risk of transfer from mother to
a newborn baby and colonization of this pathogen could potentially reduce the rates of
neonatal meningitis and sepsis. Mice models that had been vaginally challenged with
GBS successfully demonstrated that a single dose of PlyGBS could cause a three log
reduction in cell titre in mice (Cheng et al. 2005). These results suggest that
endolysins may be used in high-risk populations to control pathogenic bacteria and
thus also disease. One study reported that endolysins have been successful in the
treatment of meningitis in rats (Grandgirard et al. 2008). This was achieved by adding
the lysin Cpl-1 directly to the brain of infant rats, which highlights the potential of
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lysins to cure an established infection. This lysin was also used effectively in the
treatment of endocarditis by delivering the enzyme intravenously by constant IV
infusion (Entenza et al. 2005).

4.2 Endolysins in diagnostics

Equally important is the application of lysins to reduce and eliminate the number of
food-borne pathogens in order to improve food safety. The use of endolysins has been
proposed for rapid identification of specific bacteria in complex bacterial mixtures.
The specific matrices of different foods make it very difficult to detect pathogens. It
was demonstrated in study that endolysin cell binding domains (CBDs) are suitable
for the immobilization and capture of bacteria required for diagnostic procedures
(Kretzer et al. 2007). To demonstrate this, magnetic beads were eoated with the CBDs
from Listeria monoeytogenes phage glutamate peptidases and were tested with
artificially contaminated foods. The CBD coated beads detected 100 CFU/g in all of
the foods tested after only six hours of pre-enrichment. After 24 hours only 0.1 CFU/g
could be detected in most of the foods. Endolysins may also be used to protect plants
as antibiotic resistance in plant bacterial pathogens can be transferred to humans via
the food chain.

4.3 Applications in the food industry

There have been many studies conducted in the dairy industry for the elimination of
bovine mastitis. This is a condition that results in the inflammation of the mammary
gland and is caused mainly by S. aureus. Mastitis is widespread in cattle and is very
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costly to the dairy industry. In one report, the effect of purified LysH5 was tested
against an exponentially growing S. aureus Sa9 strain in milk (Obeso et al. 2008).
Milk has a high content of lipids and proteins, and a pH ranging from 6.4 to 6.8. The
results showed that LysH5 was capable of killing actively multiplying staphylococci.
.A.t an inoculation level of 10^ CFU/ml, 160 U/ml of LysH5 to the pasteurized whole
fat milk reduced the viable counts to undetectable levels in four hours. When 80 U/ml
LysHS was used, the inhibitory effect was only observed in the first 60 minutes. At
lower inoculation levels (10 CFU/ml), the addition of 45 U/ml eliminated the
staphylococci in four hours. A consideration when using lysins as a means to control
foodborne diseases is their stability on food products and in food processing facilities
(Oliveira et al. 2012). Concerns with the effects of the temperature, pH and shelf life
of food must be taken into aecount as these can have varied effects on endolysins.
Most bacteria have an optimum pH of 7 and the biochemical activities of indigenous
baeteria ean alter the pH of food products (Yoong et al. 2006).
CorktastOTteofTecMoloSy

To allow for efficient biocontrol, the aetivity of an endolysin activity under different
temperatures should be detennined. Many lysins have retained aetivity over a wide
range of temperatures. The endolysin Cpl-1 was shown to be stable for over 30 min at
45°C, at 4°C for over six months and for a minimum of three weeks at 37°C (Loeftler
et al. 2003). The endolysin LysZ5 was found to effectively inhibit Listeria
contamination in soya milk after three hours at 4°C (Zhang et al. 2012). At higher
temperatures, the Thermus aquatieus phage phiIN93 endolysin has an optimal activity
between 60 and 120°C (Matsushita and Yanase, 2009). The host thermophilie
bacterium of the same name was isolated from hot spring soil and can grow at 70°C.
The L. monocytogenes amidase peptidases HPLl 18 and HPLP35 were also tested for
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temperatures range (Schmelcher ct al. 2012). HPLP35 was said to unfold at 50°C due
to its drop in activity after incubation at this temperature. In contrast, HPL118 was
reported to retain its activity when kept at 90°C for 30 minutes.

Alternative non-thenual treatments for eliminating unwanted bacteria are now being
explored. High hydrostatic pressure (HHP) is one example. As HHP can be used at
low temperatures, it allows food to better retain its product properties and when used
in combination with antimicrobial compounds, it allows for food stabilization and
shelf-life prolongation (Tabla et al. 2012). So far, apart from chemical agents, no
biological compounds can kill bacteria as rapidly as endolysins. The term enzybiotics
was coined to describe the highly effective activity lysins have for the control of
disease (Nelson et al. 2001).
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5. Engineering of endolysins

Modular structure appears to be an advantage as it enables altering the binding
speeificity and enzymatic activity of an endolysin by replacing either the catalytic or
cell binding domain with a corresponding domain from another enzyme (Lopez et al.
1997). This gives the potential for the creation of chimeric enzymes with new features
such as a broader range of bacterial targets. Some of the earliest studies on chimeric
enzymes involved swapping the cell binding domains of the pneumococeal autolysin
lytA and the phage endolysin Cpl-1 (Diaz et al. 1990). According to Proenca et al.
(2012), new chimerical endolysins were construeted by fusing the CBD of Lys87 to
the highly soluble CDs of two Enterocoeeus faeealis phage endolysins, Lysl68 and
Lys 170.This resulted in two highly soluble lytie enzymes that are broadly active
against a large many S. aureus strains, including MRSA, and against other
staphylococcal, streptococcal, and enterococcal species. Two other chimeric lytic
enzymes were developed by fusing the mature form of lysostaphin to either the native
B30 lysin an anti-streptococcal enzyme or its N-terminal enzymatic CHAP domain
(Donovan et al. 2006a). The lysostaphin and full B30 lysin created the enzyme 443Lyso. Lysostaphin and the truncated B30 created the enzyme 182-Lyso. It was found
that the fusion protein maintains the lytie properties of both parent proteins. B30 is a
443-aa peptidoglycan hydrolase that contains two hydrolytic domains and a CHAP
endopeptidase domain and an Acm muramidase domain. B30 is known to lyse
mastitis causing pathogens such as S. agalactiae, Streptocoeeus dysgalactiae and
Streptocoecus uberis. Lysostaphin was previously shown to target the major mastitiscausing pathogen S. aureus. When the B30 endolysin is fused to lysostaphin, the
product is bactericidal for all four pathogens and maintained antibacterial ranges
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typical of the parental enzymes. In another study, it was shown that, Lysl6, a S.
aureus phage P68 endolysin exhibits muralytic activity against clinical isolates of S.
aureus. However, this enzyme is insoluble. To improve the solubility, the N-terminal
enzymatic CHAP domain of Lysl6 was coupled to the C-terminal cell wall-binding
domain of the PI 7 minor coat protein (Manoharadas et al 2009). The chimeric P1617 was soluble and successfully lysed S. aureus in vitro. Also, the enzyme increased
the sensitivity of the S. aureus towards gentamicin. This was most likely caused by
the enzyme inereasing the penetration of the gentamicin through the staphyloeoceal
cell wall. More reeently, two more fusion enzymes have been created, ASA2-E-LysoSH3b and ASA2-E-LysK-SH3b (Schmelcher et al. 2012). These enzymes were
fonued by the fusion of the ASA2 endopeptidase domain to either the CBD of
lysostaphin or the staphyloeoecal phage lysin LysK. It was found that both chimeras
were active against all 16 strains of bovine mastitis tested. When added to heat treated
milk, whilst both ehimera enzymes reduced the bacterial numbers the cells that were
exposed to ASA2-E-LysK.-SH3b resumed growth. Due to the short half-life of lysins,
it may be necessary to modify them with the Fc region of IgG or polyethylene glycol
(PEG) to extend their activity in vivo to several hours (Walsh et al. 2003). PEG is
non-toxic, non-immunogenic, non-antigenic, highly soluble in water and FDA
approved (Veronese, 2005).
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6. Endolysins in synergy with other antimicrobials

Unlike antibiotics, which are usually broad-spectrum, lysins specifically kill the
species of bacteria from which they were produced. This means that while the enzyme
will display activity against the disease organism, it will have little to no effect on the
nornial human bacterial flora. Nevertheless in some eases it is possible to identify
phage enzymes with broad lytic activity, such as PlyV12 which is an enterococcal
phage lysin.

PlyV12 has a very broad lytic spectrum and shows activity against

enterococci and other Gram-positive pathogens such as S. pyogenes and S. aureus,
making it one of the broadest acting lysins identified (Proenca et al. 2012). In most
cases, broad-speetrum endolysins may show low activity or are difficult to produce in
large quantities (Fischetti, 2008). This is commonly reported for S. aureus phage
endolysins. Most of these problems are due to insolubility, incorrectly folded proteins
and inclusions bodies. The applications of lysins would benefit from modifications
extending their activity.

The application of two different lysins may kill infection more effectively, and
significantly decrease the emergence of enzyme-resistant mutants. The endolysins Pal
and Cpl-1, were tested for their in vitro activity, both alone and in combination,
against several serotypes of S. pneumoniae, including penicillin-resistant strains.
These lysins have very different N- tenninal catalytic domains but share a similar Cterminal choline cell-binding domain (Fischetti, 2008). Exposure to both enzymes
lead to the lysis of pneumococci and a clear synergistic effect was observed when
both enzymes were used (Loeffler et al. 2003). In vivo, the combination of the two
lysins with different peptidoglycan specificities was found to be more effective in
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protecting against disease than each of the single enzymes (Jado et al. 2003). In this
publication, 2.5 pg of both Cpl-1 and Pal were injected into mice one hour after
inoculating with S. pneumoniae and this completely protected the mice from
infection. However, when 5 pg of only Cpl-1 or Pal was injected, this did not protect
the animals from the infection. Another study that focused on the activity of the S.
aureus bacteriophage endolysin HydH5 and its derivative fusions proteins showed
antimicrobial synergy with the endolysin LysH5 (Rodriguez-Rubio et al. 2012).

The right combination of enzyme and antibiotic may also prevent of antibioticresistant bacteria as well as reinstate the use of certain antibiotics for which bacterial
resistance has developed. A synergistic effect was found when the pneumococcal
lysin Cpl-1 was used in combination with gentamicin or penicillin (Djurkovic et al.
2005). Cpl-1 acts synergistically with gentamicin against the strain for which the
penicillin Minimum Inhibitory Concentration (MIC)s are lowest, while the
combination of Cpl-1 and penicillin acted synergistically against the strain for which
the penicillin MIC is highest. Both nisin and the endolysin LysH5 were also combined
and their synergistic effect was observed in milk (Garcia et al. 2010). Nisin inhibits
the multiplication of S. aureus in pasteurised whole fat milk. However, LysH5 does
not have much of an inhibitory effect on cell growth regardless of contamination
level. When a mixture of both nisin and LysH5 was added, the staphlococci were
eliminated after six hours of incubation. These results suggest that LysH5 activity
might be increased by the permeabilization of the cytoplasmic membrane by nisin and
partial activation of autolysins by nisin may occur which would facilitate LysH5
activity. Lysostaphin is a metalloproteinase extracted from Staphyloeoccus simulans.
This enzyme is a potent antimicrobial against S. aureus through digestion of the
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peptidoglycan with high specificity. Development of bacterial resistance to
lysostaphin is very possible as the bacteria can alter the interpeptide bridge making it
more resistant to cleavage by lysostaphin (Becker et al. 2008). T\\q femA gene adds
the second and third glycines to the pentaglycine cross bridge, although if mutations
occur, this gene may become nonfunctional. Therefore, one mechanism of resistance
to lysostaphin involves mutations affecting the femA gene. The result of this is
monoglycine cross-bridges and the S. aureus will be completely resistant to the
lysostaphin. When in vitro and in vivo trials exposed MRSA to sub-inhibitory levels
of lysostaphin, the MRSA mutated becoming more resistant to the enzyme (Kusuma
and Kokai-Kun, 2005). The endolysin LysK. was found to be synergistic with
lysostaphin wwhen challenged against MRSA (Becker et al. 2008). It was reported
that when combined the antimicrobial activity of these enzymes was greater than
when used individually.
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7. Resistance to endolysins

Endolysins, in an attempt to prevent being trapped inside the host cell, have evolved
to target specific and essential molecules in the bacterial cell wall. Thus, it is highly
unlikely that bacteria will develop a resistance to these enzymes. An example is the
pneumococcal lysin Cpl-1. The receptor for this enzyme is cholin, which is an
essential amino alcohol present in the pneumococcal cell wall (Loeftler et al. 2001).
Even with repeated exposure of S. pneumoniae and to low concentrations of lysin in
liquid culture, enzyme resistant bacteria have not been identified (Loeftler et al.
2001). In another study, Baeillus species were exposed to chemical mutagens such as
methanesulfonic acid ethyl ester. These mutagens increased the resistance of the
bacteria to antimicrobials such as streptomycin and novobiocin. However, the bacteria
remained completely sensitive to the lysin PlyG (Sehuch et al. 2002). Currently, the
only factor, which may contribute to bacterial resistance, is possible changes in cell
wall structure of stationary phase bacteria. These changes might be brought about by
an increase in the number of cell wall associated proteins and polysaccharides as well
as an increase in peptidoglycan cross-linking (Pritchard et al. 2004).

7.1 Gram-negative bacteria

Gram-negative bacteria display a greater resistance to endolysins as they have an
extra outer membrane surrounding their peptidoglycan. Whilst this membrane
prevents access by the hydrophilic lytic enzymes, EDTA and detergents may disrupt
it. When this layer is degraded, the Gram-negative cells will then become sensitive to
endolysins (Loessner 2005). For example. Pseudomonas aeruginosa was reduced four
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log units in a time interval of 30 min, when EDTA was eombined with the lysin
ELI 88 (Briers et al. 2011). However, it should be noted that many of the agents used
to disrupt the outer membrane of the Gram-negative cell often also disrupt eukaryotic
cell membranes and this should be taken account when determining the practicality of
using endolysins for Gram-negatives.

outer membrane

peptidoglycan

peptidoglycan

plasma
membrane
a. Gram-positive cell

plasma
membrane
b. Gram-negative cell

Fig 4: The difference in structure of the cell wall in Gram-positive and Gram-negative
bacteria. The Gram-negative cell has an extra outer membrane protecting the peptidoglycan
which is make it more difficult to control these cells with endolysins.

7.2 Biofllms

Not much work has been conducted on endolysin activity in biofilms. However, the
staphylococcal phage lysin SAL-2 has been shown to successfully hydrolyze
staphylococcal

biofilms with

the efficiency of lysostaphin

at

comparable

concentrations (Son et al. 2010). The endolysin Phil 1 was shown to eliminate static
staphylococcal biofilms (Sass and Bierbaum, 2007). The endolysin was able to
eliminate biofilms of S. aureus NCTC8325, with an efficiency that was not much
lower than that of lysostaphin. It is assumed that the endolysin destabilized the
biofilm due to the rapid lysis of sessile cells, which could be located either in the
extracellular matrix or between the matrix and its surface (Sass and Bierbaum, 2007).
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The results from these studies alone provide evidenee that endolysins could be applied
either alone or with other antimicrobials as a means of infection elimination.

8. Safety and Immunogenicity

Endolysins are proteins and have been shown to stimulate an immune response if
administered systemically or mucosally (Fischetti, 2008). Ihis response might be
expected to interfere with the lysin and decrease its activity. The systemic use of
lysins can result in an increase in c>^okine production as a result of bacterial debris
being released (Fischetti, 2008). To explore this, endolysin Cpl-1 was tested in rats for
its lytic activity against untreated endocarditis due to S. pneumoniae WB4 (Entenza et
a/. 2005). Cpl-1 acted more rapidly than the control vancomycin however even at
high doses, the vancomycin induced a less pronounced cytokine release than Cpl-1.
Presumable, the fast release of cell wall fragments from Cpl-1 activity resulted in the
higher cytokine levels. To detemiine whether an immune response would affect lysin
activity, rabbit hyperimmune serum raised against Cpl-1 was assayed for its effect on
lytic activity (Loeffler et al. 2003). It was found that highly immune serum slows but
does not block the killing of S. pneumoniae by Cpl-1. Similar results were obtained
from in vitro experiments performed with antibodies directed to B. anthracis PlyG, S.
pyogenes PlyC and S. pneumoniae Pal. When high titre of these antibodies were mixed
in vitro with endolysins, killing slowed but not stopped (Fischetti, 2005, Loeffler et
al. 2003). Three doses of the Cpl-1 enzyme were given intravenously to mice and in
five out of six cases the mice tested positive for the Immunoglobulin G (IgG) against
Cpl-1. This only had a moderate inhibitory effect on activity. These mice were then
challenged intravenously with pneumococci and after ten hours were treated with
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200|ig Cpl-1. After only one minute, the lysin redueed the infeetion in the Cpl-1immunized mice to the same degree as the naive mice (Jado et al. 2003). This gives
support to the hypothesis that endolysin antibodies have minimal neutralizing effect.
A similar experiment by (Rashel et al. 2007) with a staphylococcal enzyme reported
that animals injected with lysin multiple times exhibited no adverse events. This can
be explained in part by the fact that the binding affinity of the enzyme for its cell wall
substrate is higher than the antibody’s affinity for the enzyme.

As peptidoglycan is not found in eukaryotic cells, it is often assumed that lysins are
unlikely to possess a threat to humans and animals. Nevertheless, some lytic enzymes
such as the endopeptidases may affect mammalian tissues. Lysostaphin has been
reported to degrade the elastin due to its high glycine content (Park et al. 1995). It is
also the possible that the prointlammatory components released during bacterial lysis
can induce or enhance inflammation and may be directly toxic for eukaryotic cells
causing septic shock and organ failure (Nau and Eiffert, 2002). However, despite the
concerns, the results from endolysin studies are encouraging. Lysins may be used
repeatedly to control bacteria in susceptible populations, such as those in hospitals,
and nursing homes without the risk of the development of bacterial resistance
(Fischetti, 2008).
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Conclusion

Endolysins are highly efficient peptidoglycan cleaving enzymes and have displayed
potential for both topical and systemic use. It has been shown that endolysins have
many important features that make them promising antibacterials. They are active
against bacteria despite their antibiotic sensitivity, act very rapidly and can be applied
against Gram-positive bacteria as exolysins. The likelihood of bacterial resistance
against endolyins is small and due to their specificity, can be regarded as safe for
mammalian use, and studies have shown that while they may stimulate an immune
response, the antibodies only have a minimal effect on the lysins. Endolysins have the
potential to be easily modified by means of genetic engineering or used in
combination with other antibacterials. As bacteriophages and therefore their lytic
enzymes are abundant in nature, endolysins represent a natural source of antibacterial
agents.
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CHAPTER 2

Optimization of production parameters for the bacteriophagederived peptidase CHAPk and establishment of standard operating
procedures for production and quality assessment
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Abstract
The gene for the bacteriophage K-derived peptidase CHAPk (Cysteine/Histidinedependant amidohydrolase peptidase.) was previously cloned in the vector pQE60 in
E. coli XL 1-Blue. Fifty batches of E. coli cells containing the vector with the CHAPk
insert were grown and induced with IPTG (Isopropyl P-D-l-thiogalactopyranoside) to
overexpress the CHAPk. This chapter describes the different parameters of
importance in the purification of the enzyme and the variations in terms of
concentration and activity observed among the fifty different batches. Parameters
were optimised on the basis of the observations made. A standard operating procedure
was also established for detennining concentration, activity and quality of the
enzyme. In this chapter the new SOPs developed have been set out in detail in the
materials and methods section. These include cultivation parameters for the culture,
lysis, SDS-PAGE, zymogram analysis, ion-exchange chromatography, desalting,
concentration-detennination, activity-detemiination, setting out parameters for
defining specific activity, pooling and filtration of the final product. The data from the
fifty batches of enzyme have been tabulated in the results section.
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Introduction

A very important part in the production of recombinant proteins is the purification
step (Christensen et al. 2007). Depending on the intended use of the protein, a
purification method that yields the best possible quantity and quality (native structure
or denatured) of protein should be chosen. For the purification of CHAPk, the
AKTAprime plus was used to purify the endolysin using cation-exchange
chromatography to >90% homogeneity. This is a compact purification system from
the instrumentation perspective. Chromatography is a highly efficient way to separate
proteins (Nielsen et al. 2008). The basis for ion exchange chromatography is the
competitive binding of proteins with differences in charge to an oppositely charged
chromatographic medium (Hedhammer et al. 2006). Proteins produced in bacteria,
must be extracted prior to purification by chromatography (Agerkvist and Enfors,
1990). Cell disruption can be brought about by mechanical means, or by the use of
chemicals which lyse the cells (Doebler et al. 2009). High-speed centrifugation is
usually needed for clarification of the crude extract obtained from cell lysis (Hochuli,
1992). Certain issues with production and purification may sometime arise, for
example, inconsistency, insolubility, low yield and low activity. It is usually advisable
to check for protein over-expression before purification as problems can often occur
in the expression stage of protein production (Savitsky et al. 2010). Most proteins can
be produced in quantities that are greater than in their native environment. However,
they are sometimes produced in a denatured, inactive form that accumulates
intracellularly as inclusion bodies. The formation of these inactive proteins appears to
be independent of the type of protein (Sahdev et al. 2008). The health and age of the
cells used will also make a difference to the quality and quantity of the protein
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expressed. If the induced cells are not incubated at the correct temperature, certain
proteins may assemble poorly in the cytoplasm of the host organism and the protein
may fold incorrectly (Sahdev et al. 2008). In addition, metabolically compromised or
older cells may not produce much protein. Biological activity is dependent on whether
or not the protein has been correctly folded. If the crude protein sample that is loaded
onto the chromatography column has had insufficient centrifugation, the column may
become clogged and will result in less protein being eluted (Berg, 2002). Frequently,
the purified sample may contain salts and other low molecular contaminants that will
need to be removed (Berg, 2002). Desalting is a simple and rapid method that will
remove these contaminants while at the same time, the proteins can be concentrated
gently and fast (Ward and Swiatek, 2009). The aim of this study was to optimise the
various parameters including culture propagation schedule, lysis, SDS-PAGE,
zymogram analysis, ion-exchange chromatography, desalting, concentration and
activity determination, defining parameters for specific activity determination,
pooling and filtration of the final product: thus inefficiencies were defined and
eliminated for future work.
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Materials and Methods

1. Preparation of bacterial growth media
1.1 Brain Heart Infusion broth

37g of BHI broth (Sigma Aldrich) was added to distilled water and made up to 1 litre
prior to sterilization by autoelaving at 121 °C for 15 minutes.

1.2 Baird Parker Agar

58 g of Baird Parker Agar (Sigma Aldrieh) was added to 950 ml distilled water and
autoelaved at 121°C for 15 minutes. This was allowed to cool to 45-50°C and 50md
egg yolk tellurite emulsion (Fluka) was added. The agar was mixed thoroughly and
dispensed into Petri dishes. Inoeulate the specimen and streak and ineubate at 35°C
for 24-48 hours.

2. Bacteria and growth conditions.
The strain Escherichia coli XLl-Blue (Agilent Teehnologies) was kept as working
culture stoek within the laboratory and had been appropriately stored in 80% glycerol
at -20°C. The cells from the glyeerol stock were routinely sub-cultured in LB broth at
37°C for 24 hours to maintain viability.
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3. Standard Operating Procedures (SOPs) for the production and
quality assessment of CHAPk

Production of CHAPk
Materials:
1. CHAPk clones: E. coli XL 1-Blue cells containing pQE60 vector with CHAP^
insert (grow culture overnight at 37°C in superbroth with ampicillin
[200pg/ml]).
2. superbroth: 32g tryptone (Sigma Aldrich) + 20g yeast extract (Sigma Aldrich)
+ 5g NaCl, dissolved in IL of distilled water. Autoclave at 121°C for 15
minutes and allow to cool down before use.
3.

Ampicillin (Sigma Aldrich): Make a stock of lOOmg/ml is made up and then
filter sterilize using a ().45pm filter.

4.

IPTG (Sigma Aldrich): A final cone, required in superbroth for protein
induction is linM. Typically a working stocking stock of O.IM should be
made up and aliquot 10ml volumes into sterile 15ml tubes. Store at -20°C.

5.

Sodium acetate (Sigma Aldrich): 50mM sodium acetate pH 6.5(Binding
Buffer).

6. Bijou bottles (autoclaved).
7.

Spectrophotometer (UV-1800,

UV

spectrophotometer,

Shimadzu) and

cuvettes.
8. Shaking incubator (Forma Incubated Benchtop, Orbital Shaker, Thermo
Scientific).
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Method:
1.

Add the ampicillin stock to IL of superbroth. (Final concentration of
amplicillin will be 200pg/ml).

2.

Inoculate the IL of superbroth with 10ml of the overnight culture of CHAPk
clones.

3. Place the culture in the shaking incubator 37°C and shake at 170 rpm.
4. Using the spectrophotometer, frequently check the OD590 of the culture until it
reaches an ODs^ of 0.45.
5. Place the culture on ice for 30 minutes.
6.

Add 10ml of O.IM IPTG to the culture and put it back into the shaking
incubator at 26°C for 14 hours while shaking at 170 rpm. (Final concentration
of IPTG is ImM).

7. Aliquot the culture into 250ml centrifuge tubes and centrifuge at 12000 rpm
for 10 minutes at 4°C. Discard the supernatant.
8.

Re-suspend each pellet in 2ml of binding buffer, pool the pellets together and
store them in 5ml bijou bottles at -80°C.
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Lysis of CHAPk
Materials:
1.

Frozen CHAPk clones in 5ml bijou bottles.

2.

BugBuster solution (Novagen).

Method:
1. Thaw the cell paste to room temperature.
2.

In a 50ml centrifuge tube, mix 5ml of cell paste with 3.5ml of BugBuster
solution.

3.

Gently mix at room temperature for 20 minutes using the Ikalabortechnic
KS501 digital roller.

4.

Centrifuge the tubes at 6000 rpm at 4°C for 20 minutes.

5.

Transfer the supernatant to a new tube and discard the pellet.

6. Centrifuge the supernatant at 6000 rpm at 4°C for 20 minutes.
7.

Keep the supernatant in a new tube and discard the pellet. Keep the tube on ice
during the purification.

Note: 3()jul supernatant at this stage can he analyzed for protein over-expression using SDS-PAGE.
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SDS-PAGE and Zymogram
Materials:
1. 30% bisacrylamide solution (3.3% C, BioRad, USA).
2. Zymogram: Overnight 50ml eulture of S. aureus DPC5246 (Dairy Products
Research Centre culture collection) in BHI. Autoclave the culture at 121°C for
15 minutes. Spin the culture at 12,000rpm for 10 minutes and remove the
supernatant. The cell pellet can he used straight away or kept at -20°C for
future use.
3.

Tris base (Sigma Aldrich)

4.

500ml of 1.5M Tris buffer pH

8.8.

Autoclave at 121 °C for 15 minutes and

store at 4°C.
5.

500ml of 0.5M Tris pH 6.8. Autoclave at 121 °C for 15 minutes and store at
4°C.

6. (10% w/v) SDS: Ig SDS is dissolved in 10ml sterile distilled water. Filter and
store at room temperature.
7.

Ammonium persulphate (Sigma Aldrich): (10% w/v required). Weigh 0.02g in
a 2ml eppendorf, make up to 0.2g with distilled water (make up same day as
making the gel).

8. 5X Electrode buffer stock solution: 9g Tris base (Sigma Aldrich), 3g SDS and
43.2g of glycine are dissolved in 550ml of distilled water. Adjust the pH with
HCl and NaOH and make up to 600ml with distilled water. Store at 4°C.
9.

1X Electrode buffer solution: Add 100ml of 5X electrode buffer stock solution
to 400ml of distilled water.
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10. Staining solution: Mix together 0.5g brilliant blue, 250ml of isopropanol and
100ml of acetic acid and make up to IL with distilled water. Store at room
temperature.
11. Destaining solution: Mix together 400ml of 100% ETOH, 70ml of acetic acid
and 530ml of distilled water. Store at room temperature.
12. Zymogram: Renaturation buffer: 25mM Tris-HCl pH8 buffer with a final
concentration of 1% triton x-100. (Dissolve lOmls of triton x-100 in 990mls
25mM Tris-HCl pH8).
13.

p-mercaptoethanol (Sigma Aldrich).

14.

Stock sample buffer (SDS reducing buffer): Mix 3.55ml of distilled water with
1.25ml of 0.5 Tris base (Sigma Aldrich), 2.5ml of 100% glycerol, 2ml of 10%
w/v SDS and 0.2ml of 0.5% w/v bromophenol blue.

15.

Working sample buffer: Mix 950pl stock sample buffer with 50pl (3mercaptoethanol.

16.

TEMED (BioRad, USA).
Note: Materials and gels are prepared in the fume hood
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Fig 1: Mini-PROTEAN 3 cell (BioRad) apparatus.y[Qi\\Qd\
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1

If samples are frozen, defrost on ice.

2. Castinu frame set up:
a.

Place the casting frame upright with the pressure cams in the open
position and facing forward on a flat surface,

b

Select a spacer plate and place a short plate on top of it.

c.

Slide the two glass plates into the casting frame, keeping the short
plate facing outwards.

Place a Short Plate on top of the
Spacer Plate.

Slide the two plates into the Casting
Frame keeping the Short Plate facing front.

Fig 2: Assembling the glass plates of the Mini-PROTEAN 3 eell apparatus.

d.

Lock the casting frame in place in the holding frame. Repeat steps 2-5
for a second gel.

e.

Place a comb completely into the assembled gel cassette. Mark the
glass plate 1 cm below the comb teeth. This is the level to which the
resolving gel is poured. Remove the comb.

f

Fill the space between the plates 1/4 way up with distilled water to
check for leaks. If leaks are observed, empty out the water and dry up
excess water with tissue paper.
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Lock the pressure cams to secure
the glass plates.

Secure the Casting Frame in the Casting
Stand by engaging the spring loaded lever.

Fig 3: Assembling the Mini-PROTEAN 3 casting stand and frame.

3. Gel preparation:
a.

Makeup 10% APS.

b

Prepare the resolving gel monomer solution in small beakers as
tbllows: 3.4ml of distilled water is added to 4ml of 30% bisaerylamide
and 2.5ml of 1.5M Tris-HCl, pH 8.8 + 0.1ml of filter-sterilised 10%
W/V SDS (fume hood).

c.

Zymogram: mix the resolving gel with the pellet of 50ml autoelaved
eells. Add 70pl of 10% APS (freshly made) and 20pl of TEMED. Mix
well with dropper and swirl well to initiate polymerization.

d.

Immediately prior to adding the resolving gel to the slides, add 50pl of
10% APS and 25pl of TEMED. Mix well and swirl to initiate
polymerisation.
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e.

Pour to the mark using a Pasteur pipette. Pour the solution smoothly to
prevent it from mixing with air.

f.

Immediately overlay the solution with water.

g.

Allow the gel to set (usually takes 15-20 minutes). Cheek any
remaining gel left in glass beaker to see if the gel has solidified.

h.

Prepare the staeking gel solution: 5.1 mis of distilled water, 2.3ml of
30% bisaerylamide, 2.5ml of 0.5M Tris-HCl pH 6.8 and 0.1ml of 10%
SDS.

i.

Immediately prior to adding the stacking gel to the slides, add 50pl of
10% APS and 30pl of TEMED. Mix well and swirl to initiate
polymerization.

j.

Mix well with a Pasteur pipette.

k.

Pipette the gel between the glass plates. Continue until the top of the
short plate is reached.

l.

Insert the desired comb between the spacers starting at the top of the
plate, making sure that the tabs at the ends of each comb are guided
between the spacers. It is easier to insert the comb starting at an angle
and insert well 1 first, then 2, 3, and so on until the comb is completely
inserted. Seat the comb in the gel cassette by aligning the comb ridge
with the top of the short plate.

m. Allow the stacking gel to polymerize for 20 minutes.

4.

Sample preparation:
a.

Add 20pl of working sample buffer to 30pl of the sample to be
analyzed.
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b. Boil the samples for four minutess, place samples back on ice.

5.

Electrophoresis module assembly:
a.

Remove the gel cassette assemblies from the casting stand.

b. Place a gel cassette sandwich into the slots at the bottom of each side
of the electrode assembly. Be sure the short plate of the gel cassette
faces inward.
c.

Lower the Inner Chamber Assembly into the Mini Tank. Fill the inner
chamber to top with 1X running buffer.

d.

Leave buffer overflow into the electrode assembly until it has reached
the indicated height. If no indications are marked then add ~200ml of
running buffer to the Mini Tank (lower buffer chamber).

c.

Carefully remove the combs from the gels.
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Remove the Giel Cassette Sandwich
from the Casting Frame.

frame.

Place Gel Cassette Sandwich into the Electrode
Assembly with the Short Plate facing inward.

Press down on the Electrode Assembly
while closing the two cam levers of the
Clamping Frame.

Lower the Inner Chamber into the Mini Tank.

Fig 4: Final assembly of the Mini-PROTEAN 3 unit.
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6. Sample loadina and gel electrophoresis:
a.

Load the samples (15pl) and the marker (8pl) into the wells.

b. Any unused sample can be frozen at -20°C and used again if needed.
c.

Attach the SDS apparatus to the powerpack and run gel at 200V for
40-50 minutes (or lower voltage for longer time.)

d.

Make sure the SDS apparatus is receiving power by checking for
bubbles in the buffer.

e.

When the gel running time is completed, cheek that the samples have
run to the end of the gel.

f.

Turn off the power supply and disconnect the electrical leads.

g.

Remove the tank lid and carefully lift out the Inner Chamber
Assembly.

h.

Pour off and discard the running buffer.

7. Stainiim the aels:
a.

Separate the glass slides and place the gels in staining solution, shaking
for at least one hour. The green, wedge shaped, plastic gel releaser may
be used to help prise the glass plates apart. Run the sharp edge of the
gel releaser along each spacer to separate the gel from the spacer.
Remove the gel by floating it off the glass plate by inverting the gel
and plate under agitating gently until the gel separates from the plate.

b. For zymogram: Place the gel into renaturation buffer, shaking at 37°C.
c.

Rinse the gels with water and place stirring in detaining solution for at
least one hour.

8. View the SDS gels under white light.
9. The zymogram is viewed under UV light.
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10. Rinse the Mini-PROTEAN 3 cell electrode assembly, Clamping Frame and
Mini Tank with distilled/deionized water after use.
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Purification of CHAPk by ion-exchange chromatography with AKTAprime Plus
system.
Materials:
1. 50mM sodium acetate pH 6.5 (Binding Buffer).
2. 50mM sodium acetate pH 6.5 with IM NaCl (Elution Buffer).
3.

20%ETOH.

4.

200mM sodium acetate in 20% ETOH (Column Storage buffer).

Flow diversion
valve

Fraction
collector

>ystem pump
Optical unit
Flow
restnctor

^

Conductivity cell

Pressure sensor
Mixer

Injection valve

Buffer valve

Gradient
switch valve

Fig 5: AKTAprime (GE Healthcare) system.
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Method
1. Turn on computer and open the PrimeView 5.0 application.
2. Turn on the AKTApnVwe system and allow it to calibrate (automatic).
3.

Ensure that the waste bottle is empty.

4.

Load test tubes into the fraction collector.

5.

Adjust the delivery arm as follows:
a.

Lower the ami and allow it to move until the tube sensor touches the
test tubes.

b. Adjust the arm so that the sensor is about 5mm below the top of the
tubes. The tubes should always be below the horizontal mark on the
tube sensor.
c.

Rotate the rack counter clockwise until the rear half of the tube sensor
rests against the first test tube.

6. With clean deionised water do a system wash:
a.

Put the inlet tubing (A1 and B) in the bottle of deionised water.

b.

Using the AKTA/^nwe system, go to templates then press ‘OK’.

c.

Go to application templates and then press ‘OK’.

d. Go to system wash and press ‘OK’.
e.

On the screen it should say: 'A,B,_,_, ok',

f

Underline the word ‘ok' then press ‘OK’,

g.

Press ‘OK’ to start run.

7.

Do a system wash a second time.

8.

Press escape.

9.

Place the two inlet tubes (A1 and B) in binding buffer.
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10. Go do a manual run as follows:
a.

Go to templates then press ‘OK’.

b. Go to application templates then press ‘OK’.
c.

Press the down arrow until reaching ‘manual run’ and then press ‘OK’.

d. Press the down arrow until reaching ‘set flow rate’ then press ‘OK’.
e.

Using the up arrow set flow rate to Iml/min then press ‘OK’.

f.

Press the up arrow until reaching where the screen says ‘Press OK to
start run’

g.

Press ‘OK’ to start the run.

11. When it has been running for approximately five minutes, take column wire
off
12. Unscrew the top of the capto-s 1ml column. If this is the first time the column
is used, remove the ‘snap-off end of the column.
13.

For first time use of the column (or for long term storage), the column should
be washed as follows:
1. Wash the column with 5 column volumes of binding buffer.
2. Wash the column with 5 column volumes of elution buffer.
3.

14.

Wash the column with 5 column volumes of binding buffer.

Let the flow from the column wire drop into the 1ml column in a drop to drop
way to avoid air bubbles .

15.

Carefully screw the column wire onto the top of the 1ml column. The drops
should then be seen coming out of the end of the column.

16.

Screw the end of the column into the machine, taking care with the column
wire.

17. Let the run continue for another 15 minutes.
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18. Monitor that the tlow through goes into the waste bottle.
19. In a sterile universal, mix 3ml lysed supernatant (unpure CHAPk) and 2ml
binding buffer.
20. End the manual run and inieet binding buffer and proteins as follows:
a.

Go to manual run again and then press ‘OK’.

b. Go to where the sereen says ‘inject valve position’ and then press
‘OK’.
c.

Underline 'inject' then press ‘OK’.

d.

Remove syringe from machine (or get a new one) and fdl with 5ml
binding buffer.

e.

Go back to ‘inject valve position’ and then press ‘OK’.

f.

Underline 'inject' again then press ‘OK’.

g.

Tap the top of the syringe to eliminate air bubbles.

h. Attach syringe.
i.

Go to ‘inject valve position’ and then press ‘OK’.

j.

Underline 'load' then press ‘OK’.

k.

Inject buffer.

l.

Repeat steps b-j.

m. Finally repeat steps b - j again but this time inject the 5ml mixture of
unpure CHAPk and binding buffer.
21. Put inlet tube A1 in binding buffer and put inlet tube B in elution buffer.
22. Press escape.
23. Press down until reaching 'stored program method' and then press ‘OK’.
24. Underline 'system' then press ‘OK’.
25. Press the up arrow until reaching program number 25 then press ‘OK’.
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26.

Press ‘run’.

27.

Analyse the real time graph produced by the PrimeView software to identify
fractions containing CHAPk (usually fractions 16 - 18 and peak size is
typically 400 - 600 mAu).

28.

Press ‘OK’ at the Method Complete prompt to finish the run.

29.

Transfer fractions containing pure

CHAPk

into a sterile eppindorf and store at

-20°C.
Note: For troubleshooting see AKTAprime manual.

mAu

UV

Cond

pH

Pressure

T emp

Cone

1600-

Fig 6: Typical real time graph of purification . The X-axis displays the time in minutes.
The numbers marked in red indicate which fraction tubes contain eluted protein. Values
on the Y-axis apply to the curx’e with the same colour as the axis markings. Dark blue
represents UV absorption units, the red line shows the conductivity, the pink line
indicates the pH level, the brown shows the pressure level, the turquoise line represents
temperature and the green line shows concentration.
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Desalting CHAPk

Materials:
1.

Purified CHAPk.

2. Amieon Ultra-15 filter tubes (10,000 MWCO, Millipore).
3.

25mM Tris pH 7.0: 3.03g of Tris base (Sigma Aldrieh) is dissolved in 900ml
of distilled water. Use 1M NaOH and 1M HCl to adjust the pH. Make the Tris
up to 1L with distilled water .

4.

Swinging bueket rotor (C412, JOUAN).

Method:
1

Fill the filter unit of the Amieon tube to 14ml with 25mM Tris pH 7.

2. Centrifuge at 4000 rpm for 20 minutes on a swinging bueket rotor.
3.

Remove the buffer from the tube and pipette out any buffer trapped in the
filter unit.

4.

Plaee 14ml of purified CHAPk into the filter unit of the Amieon tube.

5.

Centrifuge at 4000 rpm for 20 minutes and diseard the flow through.

6. Repeat steps 4-5. Depending on the eoncentration required, the tube can be
refilled with buffer instead of CHAPk.
7.

Fill the filter tube up to 14ml once more.

8. Centrifuge at 4000 rpm for 25 minutes.
9.

Discard the flow through and transfer the CHAPk (trapped in the filter unit)
into a sterile eppendorf Store at -80°C.

69

Determination of CHAPk concentration

Materials:
1.

Pierce® BCA Protein Assay Kit (Thermo Scientific).

2.

Microtitre plate.

3.

Purified and/or desalted CHAPk protein.

4.

Plate reader (SpectraMax 340, Molecular Devices).

5.

25mM Tris pH 7.

Method:
Table I: Preparation of BSA standards.

Volume of Diluent

Volume and source of BSA

Final BSA Concentration

(id)

(Ml)

(pg/ml)

A

0

300 of stock

2,000

B

125

375 of stock

1,500

C

325

325 of stock

1,000

D

175

175 of vial B dilution

750

E

325

325 of vial C dilution

500

F

325

325 of vial E dilution

250

G

325

325 of vial F dilution

125

H

400

100 of vial G dilution

25

I

400

0

0=blank

Vial
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1.

Dilute the eontents of one Albumine Standard (BSA) ampule into several
clean vials, preferably using the same diluents as the sample(s)(use 25mlVl
Tris).

2. Each 1ml ampule of 2mg/ml Albumin Standard is sufficient to prepare a set of
diluted standards for either working range suggested in the table.

Note: There will he sufficient volume for three replications of each diluted standard.

3. 200pl of working reagent (WR) reagent is required for each sample in the
microtitre plate procedure. Use the following fomiula to detemiine the total
volume of WR required:

(# standards ^ # unknowns) x (# replicates) x (vol. of WR/sample) = total vol. WR required.

4.

Prepare WR by mixing 50 parts of BCA Reagent A with 1 part of BCA
reagent B (ratio 50:1, Reagent A:B). For the above example, combine 50ml of
Reagent A with 1ml of Reagent B.

Note: When Reagent B is first added to Reagent A, turbidity is ohsen’ed that quickly disappears
upon mixing to yield a clear, green WR. Prepare sufficient volume of WR based on the number of
samples to he assayed. The WR is stable for several days when stored in a closed container at
room temperature.
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5.

Preparation of dilutions of CHAPk (required in triplicate for each dilution):

a.

1/5 dilution: 5^1 of pure CHAPk is diluted with 20pl of 25mM
Tris.

b.

1/10 dilution: 2.5)al of pure CHAPk is diluted with 22.5pl of
25mIVI Tris.

c.

1/20 dilution: 1.25pl of pure CHAPk is diluted with 23.75pl of
25mM Tris.

6.

Pipette 25pL of each standard or unknown sample replicate into a microtitre
plate well (working range = 20-2,00()pg/ml).

Note: If sample size is limited, lOpL of each unknown sample and standard can he used (sample to
iVR ratio

=

1:20). However, the working range of the assay in this case will he limited to 125-

2, OOOpg/ml.

I.

Add 200pL of the WR to each well and mix plate thoroughly on a plate shaker
for 30 seconds.

8. Cover plate and incubate at 37°C for 30 minutes.
9.

Cool plate to room temperature.

10. Measure the absorbance at 562nm in a microtitre plate reader.
II. Subtract the average 562nm absorbance measurement of the blank standard
replicates from the 562nm measurements of all other individual standard and
unknown sample replicates.
12. Prepare a standard curve by plotting the average blank-corrected 562nm
measurement for each BSA standard vs. its concentration in pg/ml. Use the
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Standard curve to determine the protein coneentration of eaeh unknown
CHAPk sample.
Note:
a.

If using cun'e-fitting algorithms associated with a microtitre plate reader, a four-parameter
(quadratic) or hest-fit curx’e will provide more accurate results than a purely linear fit. If
plotting results by hand, a point-to-point cur\>e is preferable to a linear fit to the standard
points.

b.

For troubleshooting refer to the BCA Protein assay kit manual (Pierce Scientific).
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Quantification of lysin activity.

Materials:
1. S. aureus strain DPC5246.
2. BHI broth (Sigma Aldrich).
3.

25 mM Tris buffer pH 7.

4.

Desalted CHAPk of known concentration.

Method:
1. Grow S. aureus strain DPC5246 at 37

in the shaking incubator to an

of 0.3 (in BHI broth). Usually, a 500ml volume of culture, upon reaching the
OD of 0.3, is aliquoted into 50ml plastic centrifuge tubes.
2. Centrifuge the 50ml tubes at 4000 g for 10 min at 4 "C (Thenno Scientific
CL30R centrifuge). Remove the supernatant. Cell pellets can be used
immediately or stored at -20 "C until required.
3.

When required, resuspend one 50ml pellet of DPC5246 cells in 1ml of 25mM
Tris buffer pH 7. Check the ODsqq in the spectrophotometer (Shimadzu UV1800) and adjust the sample accordingly with buffer until an ODsqo of 1.9 is
achieved.

4.

Add 100 pi of the prepared bacterial suspension to wells in a 96-well
micotitre-plate. Minimum well usage is 3 control wells (cells in buffer alone)
and 3 test wells (cells in buffer + enzyme)

5.

To each control well (containing 100 pi of cell suspension) add 100 pi of 25
mM Tris buffer pH 7. To the test wells add lOOpl of purified lysin* in 25 mM
Tris buffer pH 7 Each different lysin concentration is performed in triplicate.
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"^serial (2-fold) dilutions of lysin from a l()()jug/ml working stock e.g. Typically for
CHAP the concentration of lysin in wells will range from 5pg/ml

6.

Monitor decrease in

ODsqo

0.5pg/ml.

at 37°C for 15 min in the microtitre plate reader

(Molecular Devices, Spectra Max 340). Typically, the

in control wells

gives an absorbance value of 0.6 nm at time 0 min.
7. At the 15 minute end-point, the lowest concentration/amount of lysin that
reduces the ODsqo by 50 % comipared to the control wells (using average
values ± standard deviation) is defined as one unit (U) of activity. In the case
of CHAPk, 5-15pg/ml (l-3pg of enzyme per 200pl well) typically
corresponds to lU of activity.
8. Calculate the Specific Activity (S.A.) of lysin:

S.A.

=

the amount of enzyme activity in each mg ofprotein (imits/mg):

S A. =

units

(enzyme activity)

mg total protein

(total amount of protein in 200 pi well)

Specific activity (S.A) of CHAPk (Batch X) is calculated to be 1000
IJ/mg

9. Express Specific Activity as U/nmol. For example:
lmgCHAPK= 18586.6g= 1 mol
= 1

X

10'^ g = ? mol

= 1 X lO'^g = 0.0000000538 mol
Img CHAPk = 53.8 nmol
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CHAPk ct^ntains 1000 units in 1 mg of protein.
Img of protein eorresponds to 53.8 nmol =

1000 U/mg

= 1000 lJ/53 nmol
=
=

1000/53 = U/nmol
18.9 U/nmol

Specific Activity (S.A.) of CHAPk (Batch X) is 18.9 U/nmoI

76

m
E.coli XI1 blue cells are grown to an OD590 of 0.5

Induce with IPTG and incubate (S) 26°C for 14 hours

Harvest cells and resuspend cell pellets in
2ml binding buffer

Lyse the resuspended cell pellets with Novagen BugBuster® Protein Extraction
Reagent

Centrifuge and keep the supernatant

Purify proteins using ion - exchange
chromatography

Fig 7: Summary of the production and purification of CHAPk

11

Pool purified protein fractions

r
Desalt pooled fractions using Amicon
Ultra -15 ml centrifugal filter tubes

Use BCA protein assay kit to detennine
concentration of desalted protein

SDS - PAGE of desalted proteins

Fig 8: Summary of the desalting and concentrating of CHAPk
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Pool all desalted vials of protein into one stock

Filter sterilise the protein stock

SDS - PAGE of protein stock

Detennine concentration of stock

Check activity units of the stock
Fig 9: Summaty of how the final CHAPk stocks were obtained.
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Results

Production and purification of multiple batches of CHAPkFifty batches of CHAPk were prepared as described in the materials and methods (see
summary on pages 74-76). As shown in Table 2, each batch (except batches 5, 8 and
19) contained 2 litres of E. coli XL 1-Blue. These cells contained the pQE60 vector
and were grown in superbroth supplemented with ampicillin (final concentration of
200pg/ml). When the cultures had reached mid-log phase, they were indueed with
IPTG to produce CHAPk Cells were harvested by centrifugation and each pellet was
resuspended in 2ml of 50mM sodium aeetate pH 6.5. The pellets were lysed using
Novagen bugbuster solution and the cellular debris was removed by centrifugation.
The resulting supernatant was purified using eation-exehange chromatography. The
purified protein was eluted into different fraction tubes and these fractions are later
pooled together for desalting.

Fractions containing purified protein were pooled into Amieon-Ultra eentrifugal tubes
and concentrated in 25 mM Tris pH 7 (Table 3).The tubes were eaeh eentrifuged three
times and the concentrated protein was trapped in between the filters of the tube. The
eoncentration of the desalted protein was quantified using the BCA protein assay kit.
The coneentrated tubes of endolysin were then pooled together to form three separate
stoeks of CHAPk. After the desalted CHAPk was pooled, each resulting stock was
then diluted with buffer, filter sterilized by passage through a 0.45pm filter and
quantified for coneentration and aetivity (Tables 4-6). In an attempt to prevent as
mueh protein as possible from being trapped in the filter, buffer was used to double in
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volume of stock with before sterilization. Unlike the previous stock, 2ml of buffer
was filtered before the stock in attempt to prevent the stock being caught in the filter.

Results obtained for the production and purification of CHAPk
Table 2: CIIAPk that w as produced, purified and pooled for desalting.

Batch
number

Original
culture
vol.
(litres)

Time
to
reach
mid
log
phase
(hours)

Total
number of
purification
runs for
this batch.

Average
peak
size
(mAu)

Fractions
containing
purified
CHAPk

1

2

5

5

225

16-18

2

2

5

5

125

16- 18

3

2

4.5

3

25

16- 18

4

2

6

6

50

16- 18

5

4

6

6

150

16- 18

6

2

5

5

50

16- 18

7

2

5.75

5

50

16 - 18

8

4

5.75

5

125

16- 18

9

2

4.5

5

50

16- 18

10

2

5

6

150

16- 18

11

2

4.5

4

125

16 - 18

12

2

5

7

450

16-18

13

2

5.5

7

350

16- 18

14

2

5.5

5

600

16 - 19

15

2

5.5

7

500

16 - 18

16

2

5.5

7

400

7-10

17

2

5.2

7

300

16 - 19

18

2

5

6

300

16

4

5

8

475

18

7- 9
19

16 - 18

Fractions
pooled
for
desalting

Filter
tube
number

>-

1

>

2

3

4

>
>

7

5

6

7
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Table 2:Cont.

Batch
number

20

Original
culture
voi.
(litres)

Time to
reach
mid log
phase
(hours)

4.5

lotal
number of
purification
runs for this
batch.

Average
peak size
(mAu)

Fractions
containing
purified
CHAPk

300

16 19

Fractions
pooled for
desalting

Filter
tube
number

-

10

350

16 19

22

450

16 18
-

12

23

450

16 18
-

13

450

16 19

14

21

24

4.5

4.5

-

-

15
25

4.5

425

16 18
-

16

26

4.5

450

16 18

17

27

4.5

500

16 19

28

4.5

450

16 18

-

-

-

19
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Table 2:Cont.

Batch
number

Original
culture
vol.
(litres)

Time
to
reach
mid
log
phase
(hours)

Total
number of
purification
runs for
this batch.

Average
peak
size
(mAu)

Fractions
containing
purified
CHAPk

Fractions
pooled
for
desalting

Filter
tube
number

29

4.5

450

16- 18

20

30

4.5

450

16- 1

21

31

4.5

500

16-1

22

32

4.5

400

7-9
23

33

34*

4.5

425

16 - 1:

250

17- 19
24

35 =

4.5

250

17- 19

36=

4.5

250

17-19
24

37=

4.5

100

17 - 19

38=

4.5

250

17-19

26

39=

4.5

300

17-19

27
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Table 2:Cont.

Batch
number

Original
culture
vol.
(litres)

Time
to
reach
mid
log
phase
(hours)

Total
number of
purification
runs for
this batch.

Average
peak
size
(mAu)

Fractions
containing
purified
CHAPk

Fractions
pooled
for
desalting

Filter
tube
number

40

4.5

350

16

19

28

41

4.5

250

16 19

29

42

4.0

400

16 19

30

-

-

-

31
43

4.5

400

16 19
-

32

44

4.5

400

17 19
-

33

34
45

4.5

300

17

19
35

46

4.5

300

16 19

36

47

5.0

350

17 19

37

48

4.5

450

17 19

38

-

-

-
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Table 2:Cont.

Batch
number

Original
culture
vol.
(litres)

Time
to
reach
mid
log
phase
(hours)

Total
number of
purification
runs for
this batch.

Average
peak
size
(mAu)

Fractions
containing
purified
CHAPk

Fractions
pooled
for
desalting

Filter
tube
number

39
49

2

4.5

6

450

17

19
40

50

2

4.5

7

400

17 - 19

41

* = This batch of unpurified CHAPk w'as not purified straight after being produced.
The impure protein was stored at -8()°C for si.x months until it was purified.
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Results obtained for the desalting and concentrating of CHAPk
Tabic 3: The cone, (mg/ml) and volume (jul) of desalted CHAPk pooled into the first
stock.
Filter tube
number

Volume of sample
after desalting (pi)

Concentration of
sample(mg/ml)

1

750

1.9

2

650

3.7

3

700

2.0

4

450

12.9

5

350

7.6

6

300

12.5

7

250

16.8

Tubes pooled

87

Table 3; Cont.

Filter tube number

Volume of sample
after desalting (pi)

Concentration of
sample(nig/ml)

8

250

12.7

9

250

14.6

10

250

19.2

11

350

8.25

12

250

19.10

13

250

16.14

14

350

6.90

15

250

16.80

16

250

12.30

17

400

12.60

18

400

11.50

19

500

25.35

20

600

11.90

21

250

6.75

22

250

6.88

23

250

11.60

Tubes pooled
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Table 3: Cont.

Filter tube
number

Volume of sample
after desalting (pi)

Cone, of sample
(mg/ml)

24

1900

0.260

25

1900

0.290

26

1200

0.315

27

1500

0.340

28

1900

0.420

29

1350

0.390

30

1400

0.370

31

900

0.590

32

1000

0.920

33

900

0.330

34

900

0.490

35

1400

0.500

36

900

1.100

37

650

0.630

38

1400

0.985

39

500

0.380

40

500

0.450

41

500

1.050

Tubes pooled
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Final concentration and activity of CHAPk stocks.
Table 4: Cone, (mg/ml) and activity of CHAPk (U/nMol) and % Efficiency of the first
stock.
Est. total Actual
Actual total
Est.
Est.
Actual
concentration volume of amount of concentration volume of amount of %
protein
protein
Efficiency Activity
stock (ml)
stock (ml)
(nig/nil)
(mg/ml)
(mg)
(mg)
(U/nMol)
8.2

3.45

28.29

1.27

9.2

11.68

41

37.17

Table 5: Cone, (mg/nd), % efficiency and activity of CHAPk (U/nMol) in the second
stock.
Est. total Actual
Actual total
Est.
Est.
Actual
concentration volume of amount of concentration volume of amount of %
protein
protein
Efficiency Activity
stock (ml)
stock (ml)
(mg/ml)
(mg/ml)
(mg)
(mg)
(lI/nMol)
13.29

5.1

67.80

3.25

6.0

19.50

28.76

371.70

Table 6:Conc. (mg/ml) and activity of CHAPk (U/nMol) and % efficiency of the third
stock.
Est. total Actual
Actual total
Est.
Est.
Actual
amount of concentration
amount of 0//o
concentration
volume of
volume of
protein
protein
Efficiency Activity
stock (ml)
stock (ml)
(mg/nil)
(mg/ml)
(mg)
(mg)
(U/nMol)

0.545

20.70

11.28

0.47

13

6.11

% Efficiency = actual total amount of protein (mg)
Est. total amount of protein (mg)

54.2

185.87

X 100

The typical length of time for the E. coli XL 1-Blue cells to reach an OD590 was 4.5
hours. However, the majority of the batches from 1 to 19 took longer than this which
indicates that the cells used were not at their optimum when expressing the protein
(Table 2). The cells were replaced with a healthier culture and this resulted in faster
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growth as well as more enzyme being produeed as shown from bateh 20 onwards. The
BugBusted supernatant was usually (with the exception of batches 34 - 37) purified
on the same day that the E. coli XL 1-Blue cells were harvested and lysed. It can be
seen from table 1 that delaying the purification resulted in less CHAPk being purified.
On average 6 -7 purifications run were carried out, however for a few batches not all
these runs resulted in any protein being given off It was found that the greater the
volume of desalted CHAPk, the less concentrated it would be (Table 3). However,
further centrifugation would reduce the volume of enzyme and a higher concentration
of protein would result. Three separate stocks of CHAPk were made. Based on the
volumes and concentrations of the desalted fractions, the final quantity of the CHAPk
stock was estimated (Tables 4-6) and finally the actual values were obtained.
Although, the actual amount of protein obtained in each case was less than what was
expected. Due to better purification and desalting yield, the second stock of CHAPk
resulted in more protein than in the first stock (Table 5). Nevertheless, doubling the
volume of stock before filtration lowered the % efficiency .Table 6 shows the data for
the third and final stock of enzyme. The concentration of CHAPk was found to be
much lower than what was previously obtained, however, the % efficiency was much
better that with the first and second stocks.
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Discussion
Fifty batches of CHAPk were produeed and from these, three separate stoeks of
enzyme were obtained. The results of this study demonstrate that CHAPk can be
efficiently expressed in a biologically-active form in E. coli and retain its catalytic
properties. However, for the first 11 batches, as seen in table 2, the purification
showed low levels of protein with some batches only reaching SOmAu (Absorption
units) in peak size. To ensure that no CHAPk was being sent to the waste instead of
being fraetionated out, it was neeessary to perform an SDS-PAGE gel with samples
taken from the tlow through. As these gels indicated that the enzyme was not being
discarded, it was assumed that the problem lay with the expression of the endolysin.
Therefore, for batches 12 onwards, a new stoek of the cells was used. This resulted in
much better expression of the enzyme. To purify the proteins, it was necessary to first
harvest the E.coli eells from eaeh bateh, resuspend the cell pellets in binding buffer
and then lyse open the eells using BugBuster^”^. Resuspended cell pellets eould be
stored at -80‘’C until needed for purifieation, although, it was found that the longer the
interval between harvesting and purifying, the less pure protein was obtained as
observed with batches 34 - 39. Cells were always bugbusted on the same day that
they were purified. Fraetions showing the highest amount of enzyme were pooled into
Amieon filter tubes to eoncentrate the protein and remove and salts which may
interfere with the enzyme aetivity. Once the filter tubes were filled to 14ml, they were
eentrifuged at 4000 rpm and the tlow through was disearded. The protein obtained
was tested for coneentration (mg/ml) and it was found that the greater the volume of
protein obtained from the tubes, the less coneentrated the samples were as can be seen
in table 3.
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The concentrated tractions were pooled again and fdter sterilised.

Finally, the

concentration (mg/ml) and activity units (U/nMol) were determined. An estimation of
concentration and volume of the each stock was based on the desalted fractions. The
first stock of protein yielded 11.68mg of protein from 42 litres of culture (on average
0.28mg of protein per litre). This yield of this stock was lower that what was
estimated (28.29mg/ml). It was expected that the actual concentration of the protein
stock would be slightly lower than estimated due to the filtering process. However,
with a % efficiency of 41%, it was decided to alter the filtering procedure. Stock
number 2 had a much better yield of protein with 67.80mg from 26 litres of culture
(average 2.6mg per litre), yet despite the higher yield of protein the % efficiency of
this stock was only 28.76%. I'his was due to doubling the volume of the CHAPk
stock with buffer. The reason for this was it was decided that when a concentrated
stock of protein was to be filtered, it can be expected that some of the stock will be
trapped in the filter. Thus by diluting the stock, the concentration of stock trapped in
the filter will be diluted also. The third and final stock of CHAPk had a low yield of
protein. 11.28mg of protein was obtained from 32 litres of culture (on average 0.35mg
per litre). A possible explanation for this is that the cell pellets from six of its batches
(12 litres) were stored at -80‘’C for over six months. The activity of all three stocks
varied considerably. The first stock had an activity of 37.17 U/nMol. This is
extremely low compared to the activities of the second and third stocks, however,
when desalting the first stock, lOmM sodium acetate pH 7 was used instead of 25mM
Tris pH 7. The difference in activity between the second and third stock can also be
explained by the fact that 6 batches of stock number three were frozen for 6 months
before use. To avoid confusion for later workers, optimum methodologies defined
from the various observations are the only ones recorded in this chapter.
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CHAPTERS

Application of the bacteriophage-derived peptidase CHAPk for elimination
of Staphylococcus aureus on the bovine udder and human skin
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Abstract
The endolysin CHAPk, known to exhibit strong antistaphyloeoccal properties and was
investigated for its potential to eliminate Staphylococcus aureus from the bovine udder and
from human skin. Solutions containing either the recombinant bacteriophage encoded
cysteine/histidine-dependant amidohydrolase peptidase (CHAPk) or the lactic acid and
chlorhexidine based teat dip Nanodual were evaluated by experimental challenge as a teat dip
and teat spray against S. aureus on excised teats and finger skin. Efficacy in both applications
was good in that the levels of S. aureus were typically reduced by three to five log cycles on
both animal and human surfaces.
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Introduction

Despite advancements in the treatment and prevention of bovine mastitis, the condition is still
a major cause of concern for farmers. Mastitis is present wherever there are cows and it has
been estimated that one third of all dairy cows are infected with some form of mastitis in one
or more quarters. Clinical mastitis occurs when the cow displays definitive symptoms of the
disease such as swelling, heat, hardness, redness, or pain of the udder. A cow is said to have
sub-elinical mastitis if she does not display the typical clinical symptoms of mastitis. With
sub-clinical mastitis there are no visible changes to the composition of the milk and therefore
it is difficult to detect (Viguier et al. 2009). Chronic mastitis is rare and results in persistent
intlammation of the mammary gland. Mastitis represents a major economic cost to dairy
fanners with losses of up to €190 per case and €60 per cow for the average milk supplier
(Berry and Amer 2006). Mastitis is the single most common reason for antibacterial use in
lactating dairy animals (Erskine et al. 2004) and the frequency of infection calls for the
development of new prophylactic and therapeutic approaches (Brouillette and Malouin,
2005). S. aureus, which is the main cause of mastitis, is ubiquitous in a cow’s environment
(Philpot, 1979). Staphylococci do not persist on healthy teat skin but readily colonize teat
canals if the skin near the teat apex is cracked and this can act as a reservoir for mastitis
pathogens. Usually a smooth muscled sphincter keeps the teat canal closed, preventing
pathogens from entering and milk from escaping (Viguier et al. 2009). After milking, the
sphincter muscle remains open for one to two hours and so bacteria present during this time
can enter the teat canal. If a cow is infected with mastitis then this will also cause the
sphincter muscle to stay open (Nguyen et al. 1998). Once inside the teat, bacteria must
survive the defence mechanisms of the udder (Sordillo and Streicher, 2002). The cells that are
not eliminated start multiplying in the mammary gland and release toxins which induces an
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immune response (Viguier ct al. 2009). If the infeetion is not efficiently treated, bacterial
levels will continue to rise until the mammary gland becomes damaged and allows
extracellular fluid components to enter the gland and mix with the milk (Zhao and Lacasse,
2008).

Blood vessels

Fig I: Bacterial invasion of the teat canal (Viguier et al. 2009).

Cows can contract mastitis regardless of age and stage of the lactation cycle but vary in their
ability to overcome an infection once it has been established (Schroeder, 2012). The majority
of infection occurs during the milking process from unsanitized milkers’ hands and teat cups.
There are different methods available to keep mastitis at relatively low and acceptable levels
in the majority of herds (Schroeder, 2012). Antibiotics currently used include penicillin,
amoxicillin, tetracycline, ampicillin, and erythromycin, however, S. aureus responds poorly
to antibiotic therapy. To overcome this it has been suggested that multiple doses of antibiotics
may increase cure rates, although this would be very costly and require close veterinary
supervision and careful monitoring of milk for antibiotic residues (Nickerson and Owens,
1989). Teat dips are widely used to prevent infection from getting into the teat, thus reducing
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the occurrences of mastitis. Many fanners wash cow udders with a sanitizing pre-dip solution
prior to milking. While this may eliminate any environmental pathogens currently on the
teats, washing before milking may not satisfactorily destroy pathogens adhering to teats at the
end of milking. For this reason it is recommended that post milking teat dips be used either as
well as or instead of pre-dipping. This will remove any milk that could serve as a medium for
microbial growth as well as removing pathogens. The most efficient method of applying post
milking teat dips, involves dipping teats in the teat dip solution shortly after the milking
machines have been removed. Under cold or rainy weather conditions, teats that have not
fully dried from dipping may chap easier (Fox, 1997). This of course will increase the cows’
chance of re-infection. In order for a teat dip to be most effective, each teat must be fully
dipped into the sanitizing solution. Depending on the size of the herd, this may be very time
consuming. The most common antimicrobial agents in teat dips are chlorhexine, chorine,
iodophor and iodine (Leslie ct al. 2005). Other disinfectants commonly used include
bronopol (Boddie and Nickerson, 2002), sodium chlorite (Hillerton et al. 2007), phenol
(Oliver et al. 1999), and quaternary amines (Pankey and Watts, 1983).

An alternative to teat dipping is spraying the teats with sanitizer. The use of a teat spray is
more efficient and reduces the risk of spillage which can occur with teat dips. Although some
drawbacks of this method is that sprayers are more expensive than teat dip cups and need to
be maintained. Also there is the likelihood that the spray pump will not spray each teat evenly
and pathogens won’t be fully eliminated. Harsh germicidal agents in many dips can also
contribute to teat skin chapping so conditioning agents are therefore often added to teat dips
to counter this (Fox, 1997). Bacteriophage endolysins, which cleave highly conserved bonds
within the bacterial peptidoglycan have received increasing attention as antimicrobial agents
due to their high target cell specificity. As theses enzymes are peptidoglycan specific, they
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will not have any effect on teat skin. In this chapter the endolysin CHAPk was evaluated as
an anti-mastitis agent and compared to the commercially available teat dip Nanodual in terms
of ability to eliminate or reduce cell numbers of 5. aureus.

Fig 2: Example of teat eiips and spray pumps used to eontrol mastitis infections.

Numerous studies have been earned out to test the efficacy of various antimicrobial agents
against S. aureus induced mastitis. When assessing the efficacy of antimicrobial agents for
treatment of bovine mastitis, in vivo experiments are associated with high costs and complex
management (Schmelcher et al. 2012). An alternative laboratory technique using excised
teats from slaughtered dairy cows has been shown to yield highly reproducible results (Watts,
1988). In this study, a CHAPk based solution and the commercial teat dip Nanodual were
evaluated for activity again the bovine mastitis strain S. aureus DPC5246.
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Materials and Methods
1. Preparation of bacterial growth media
1.1 Brain Heart Infusion broth

37g of BHI broth (Sigma Aldrich) was added to distilled water and made up to 1 litre prior to
sterilization by autoclaving at 121°C for 15 minutes.

1.2 Baird Parker Agar

58g of Baird Parker Agar (Sigma Aldrich) was added to 950ml distilled water and autoclaved
at 121°C for 15 minutes. This was allowed to cool to 45-50°C and 50md egg yolk tellurite
emulsion (Fluka) was added. The agar was mixed thoroughly and dispensed into Petri dishes.
Inoculate the speeimen and streak and incubate at 35°C for 24-48 hours.

2. Bacteria and growth conditions.
The strain S. aureus DPC5246 (Dairy Products Research Centre culture collection) was kept
as working culture stock within the laboratory and had been appropriately stored in 80%
glycerol at -20°C. The cells from the glycerol stock were routinely sub-cultured in BHI broth
at 37°C for 24 hours to maintain viability.

3. Overexpression and purification of CHAPk
CHAPk was heterologously overexpressed in Escherichia coli XL 1-Blue (Agilent
Technologies). Cells were harvested by eentrifugation and resuspended in 50mlVI sodium
acetate pH 6.5.The pellets were lysed by Novagen BugBuster solution (Merck) and the
resulting supernatant was purified by ion-exchange chromatography to high purity using the
AKTAprime plus automated chromatography system. Fractions containing CHAPk were
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pooled and concentration using Amicon filter tubes (Millipore). The concentrated enzyme
was quantified with the BCA Protein Assay Kit (Pierce Scientific) and its activity was
determined using a turbidity reduction assay.

4. Teat spray/dip preparation
Nanodual is a commercially available lactic-acid and chlorhexidine based teat dip.

5. Evaluation of CHAPk as an anti-mastitis/anti-staphylococcal spray.
In a laminar flow, hood four excised teats were suspended on sterile twine using sterile
wooden clothes pegs, as shown in Fig 2. The excised teats were obtained from a slaughter
house and were thoroughly cleaned and disinfected prior to use. Before use, they were
washed in 70% ethanol and allowed to dry.

Fig 3: Excised teats suspended in a laminar flow' hood.

Each teat was dipped into 15ml of S. aureus bovine mastitis strain DPC5246 (overnight
culture washed twice with buffer). One teat is allowed was to dry for 15 minutes. The other
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three teats were allowed to dry for five minutes and sprayed with 25 Mm Tris pH 7 (Sigma
Aldrieh), CHAPk (200pg/ml) and Nanodual respeetively and allowed to dry for a further 10
minutes. After drying, all three teats were dipped into 10ml of Ringers solution (Sigma
Aldrieh) for 20 seeonds. Serial dilutions were made from the eells in the Ringers and these
dilutions were then spot plated on Baird Parker agar (Sigma Aldrieh) and ineubated at 37°C
for 24 hours. Serial dilutions were earried out by pipetting lOOpl of the Ringers ‘wash’ into
900pl of fresh Ringers solution. This dilution was mixed by pipetting up and down a number
of times. lOpl of eaeh dilution were then placed as 'spots' in triplicate on an agar plate and
allowed to dry before incubating. After incubation, the number of colonies fonned in each
lOpl spot was noted and calculated to give the number of colony fonning units per ml.
Note: For human skin applications, the methodology was essentially the same as with the teats in

terms of application of cells, endolysin etc. and staphylococcal enumeration.

6. Evaluation of CHAPk as an anti-mastitis/anti-staphylococcal dip.
This challenge was earned out under similar conditions as described above. Each teat was
dipped into 15ml of S. aureus bovine mastitis strain DPC5246 (overnight culture washed
twice with buffer). One teat is allowed was to dry for 15 minutes. The second, third and
fourth teats were allowed to dry for five minutes, dipped in 3()ml of 25 Mm Tris pH 7 (Sigma
Aldrich), CHAPk (200pg/ml) and Nanodual respectively and allowed to dry for a further 10
minutes. After drying, all three teat were dipped into 10ml of Ringers solution (Sigma
Aldrich). Serial dilutions were made from the cells in the Ringers and these dilutions were
then spot plated on Baird Parker agar (Sigma Aldrich) and incubated at 37°C for 24 hours.
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7. Bacterial titre determination by spot plating.
Routine titre detennination was achieved by spot-plating. Briefly, lOOpl of the culture was
added to 900pl of Ringers solution. This dilution was mixed by pipetting up and down a
number of times. A serial dilution was carried out and lOpl of each dilution was placed as
'spots' in triplicate on an agar plate. The plates were then incubated at 37°C for 24 hours.
After incubation, the number of colonies fornied in each lOpl spot was noted and calculated
to give the number of colony forming units per ml.
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Teat 1

Teat 2

Teat 3

1

i

Teat 4

'eats dipped in DPC5246 (titre xlO^ CFU/m )

\

1

1

Left to dry for five minutes

1

Left to dry tor 15
minutes
Dipped in buffer

1

4

1

4

Dipped in CHAPk

Dipped in

(20()pg/ml)

Nanodual

1

4

Left to dry for further ten minutes

Teats dipped in ringers solution

Ringers solutions are serially diluted and dilutions are spot-plated

Plates are incubated at 37°C for 24 hours

Fig 4: Overy’iew of teat tip procedure.
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Results

Evaluation of performance of CHAPk in a dip application for bovine udders and human
fingers

The CHAPk endolysin was evaluated as a dip against the bovine mastitis strain S. aureus
DPC5246. The enzyme was applied on excised cow teats (Fig 5a) and finger skin (Fig 5b).
All challenges were carried out nine times and the results shown in the Figs below are the
averages of each trial. Nanodual antistaphylococcal solution was used as a control
antimicrobial agent.
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Fig 5: The effect of CHAPj^ used as an anti mastitis dip on (a) excised teats and (b) finger skin. The Xaxis displays the log CFU/ml S.aureus DPC5246 on the skin after treatment. The blue bar shows the
numbers of S. aureus after no treatment, the red bar show the number of cells present after treating
with buffer, the green bar refers to treatment with CFlAPn and the purple bar shows the number of
cells still present after treatment with Nanodual. Error bars represent standard errors of the means
from all separate experiments.

The CHAPk solution and Nanodual solution were quite potent when applied as a dip (Fig 5a).
The enzyme solution reduced the viable cell counts by six logs. The control Nanodual cleared
all the cells from both the excised teats and finger skin. The CHAPk dip was also very
effective at reducing the numbers of mastitis cells on the excised teats (Fig 5a). Dipping the
teats in solution caused one log reduction in cell numbers as noted by the cell counts after
treating with buffer. A further five log CFU/ml drop was observed after treating with the
enzyme.

08

Evaluation of performance of CHAPr in a dip application for bovine udders using
lower and more realistic staphylococcal levels

The above experiments all used S. aureus at very high cell titres (xlO CFU/ml) so the
CHAPk teat dip was also evaluated at the lower inoculation of xlO^ CFU/ml. It was not
possible to evaluate lower levels than 10^ CFU/ml due to the fact that the washing step in the
procedure involved physieal removal of a signifieant quantity of eells.
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CHAPk

, ..

(2(X)ug/ml)

Nanodual

Fig 6: The effect of CHAP^ used as an anti mastitis dip on excised teats. The X-axis displays the log
CFU/ml S. aureus DPC5246 on the skin after treatment. The blue bar shows the numbers of S.aureus
with no treatment, the red bar show the number of cells present after treating with buffer, the green
bar refers to treatment with CHAP^ and the purple bar shows the number of cells still present after
treatment with Nanodual. Error bars represent standard errors of the means from all separate
experiments.
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At a lower cell litre, although effective, the CHAPk dip did not work any better than in the
previous challenge done at 10^ CFU/ml. The buffer solution showed a one log drop resulted
from the physical dipping action. The endolysin treatment gave a further 4.5 log CFU/ml
drop in viable counts and Nanodual eliminated all S. aureus on the teat.

Evaluation of performance of CHAPk in a spray-on application for bovine udders and
human fingers

The CHAPk treatments were also evaluated by applying them as a spray. This was again
carried out using excised teats (Fig 7a) and finger skin (Fig 7b). Nanodual antistaphylococcal
dip was used as a control antimicrobial. The mean results are shown with error bars
representing standard errors.
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Fig 1: The effect of CflAP/^ used as an anti mastitis spray on (a) excised teats and (h) finger skin. The
X-axis displays the log CFV/ml S.aureus DFC5246 on the skin after treatment. The blue bar shows
the numbers of S. aureus after no treatment, the red bar show the number of cells present after
treating with buffer, the green bar refers to treatment with CHAPf^ and the purple bar shows the
number of cells still present after treatment with Nanodual. Error bars represent standard errors of
the means from all separate experiments.

To detennine whether the reduetion in cells numbers could be due to the physical et'fect of
spraying as opposed to the activity of the CHAPk or Nanodual, buffer was sprayed on to the
skin as a control. From the above chart, it can be seen that CHAPk does work as a spray (Fig
7b). While the action of spraying caused a three log CFU/ml reduction in cells, there is a
three log CFU/ml reduction in viable counts from the CHAPk treated finger compared to the
buffer treated finger. Nanodual completely eliminated the S. aureus on the skin. The CHAPk
spray did not appear to have as much of an effect on the excised teats as it did with the finger
skin (Fig 7a). The physical impact of the spray was a reduction of 0.5 log CFU/ml and the
effect of the CHAPk itself was only one log CFU/ml. Nanodual also had poor activity with
only a one log reduction in cell numbers.
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Discussion

Despite considerable advances in the understanding and treatment of bovine mastitis, this
disease continues to extremely difficult to control. Worldwide mastitis is a considerable cause
of financial problems throughout the dairy industry (Guinane et al. 2008). The quantity of
bacteria that a cow is exposed to is dependant on the animals’ environment. However,
through appropriate management practices, their environment can be controlled to reduce this
exposure and enhance resistance to udder disease. Early detection of infection is vital for
elimination of infection and the prevention of mammary tissue damage, however, even with
stringent control programs, mastitis is still likely to occur (Viguier et al. 2009). Nowadays, as
an alternative to the use of antibiotics other measures for reducing infection are being
employed. The concept of applying post-milking teat sanitizers by dipping and spraying is a
popular method of controlling mastitis in dairy herds, especially where the milking operation
is mechanized. The recommended protocols for evaluating the efficacy of teat dips are
published by the National Mastitis Council (USA) (Vicario et al. 2009). Many studies on the
evaluation of anti-mastitis therapeutics have been carried out in field trials, although these are
time-consuming and expensive. Studies using excised bovine teats have been shown to be an
effective and less costly screening method (Watts, 1988). The endolysin CHAPk is a single
domain truncated derivative of the phage encoded endolysin LysK and has previously been
shown to demonstrate activity against S. aureus strains. The Nanodual dip is a ready-to-use
antibacterial based on the chemical antiseptic chlorhexidine and lactic acid, and is frequently
used for pre and post milking applications either by spraying or teat immersion.
Chlorhexidine is an effective anti-mastitis agent and works by precipitating bacterial cell
contents (Boddie et al. 1997). CHAPk in contrast is a non-chemical agent, which would be
less aggressive on skin.
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To detemiine the ability of CHAPk as a non-chemical anti mastitis therapeutic, challenge
experiments against the bovine mastitis strain S. aureus DPC5246. Given the importance of
human skin on spread of S. aureus in nosocomial infections, the excised bovine teats work
was duplicated using human fingers. This had the added advantage of showing whether the
roughness of the teat skin by comparison with human finger skin would affect the outcome of
the challenge. The treatments were tested as both a spray and a dip. Teat spraying can be an
effective method of mastitis treatment. However, it is recommended that cows be sprayed
twice around the teats and underneath in order to give sufficient cover. When carrying out the
spray analysis on the fingers and teats, they were completely sprayed and left to air dry. It can
be seen from Fig 5a that the CHAPk spray on smooth skin resulted in a three log CFU/ml
reduction in S. aureus counts. I'he physical effect of the spraying led to a further three log
CFli/ml reduction in cells numbers. The chemical Nanodual however completely eliminated
the S. aureus from the finger. The teat skin has more grooves for the S. aureus cells to collect
under and as expected, the CFIAPk spray was not as effective as with the smooth finger skin
(Fig 7a). Even the chemical Nanodual was unable to eliminate the cells from the rough teat
skin. It has been stated that teat treatments should reduce the bacteria on teats by at least three
logs in order to be considered effective (Watts, 1988). With this in mind, spraying was
considered ineffective and it was decided to evaluate CHAPk as a dip instead.

Dipping or immersion is the generally more widely used than spraying as it uses less solution
and guarantees better coverage of the teat. When the CHAPk dip was used on smooth finger
skin (Fig 5b), it was effective against reducing S. aureus present on the skin and thus one
could conclude that it may have an application to reduce spread of MRSA in hospital settings.
It was also highly effective in eliminating S. aureus on the bovine teat and has the added
advantage of being non-chemical in nature and at neutral pH and thus would result in less
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skin chapping (due to the chlorohexidine and lactic acid), which is common on the cow
udder.
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CHAPTER 4

Characterization of the activity of the bacteriophage-derived peptidase
CHAPk in milk
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Abstract
Bacteriophage endolysins are being eonsidered as new antimicrobials for the control of
pathogens in food. Staphylococcus aureus can produce enterotoxins responsible for food poisoning
in humans. This pathogen is also recognized as a frequent cause of subclinical mastitis in dairy cows
and milk from mastitie cows. The endolysin CHAPk is a 165-amino aeid truneated derivative
of the Staphylococcus aureus bacteriophage K endolysin (LysK) that works by cleaving the
peptidoglycan of the staphylococeal cell wall. The CHAPk endolysin was overexpressed in
Escherichia coli and purified enzyme was evaluated for activity in milk using challenge assays
against the bovine mastitis isolate S. aureus DPC5246.
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Introduction

Staphylococcus aureus is a Gram-positive pathogen responsible for human and animal
illnesses. It has been frequently isolated from bovine mastitis (Hata et al. 2006). The ability
of S. aureus to eause a wide range of diseases may be assoeiated with its eapacity to produee
of a range of extracellular toxic compounds enterotoxins (Boynukara et al. 2008).
Staphylococcal enterotoxin (SE) production is a problem that leads to the staphylococcal food
poisoning outbreaks in humans as the third most common food intoxication in the world
(Medved’ova et al. 2009). It is estimated that 20% of the human population are long-term
carriers of this bacterium (Kluytmans et al. 1997). S. aureus is typically found on human skin
or mucosa, in the hair, in the gastrointestinal and urogenital tracts and is recognised as a
cause of subclinieal mastitis (Obeso et al. 2008). Bovine mastitis is an inflammatory response
to infection of the mammary gland and these infeeted glands are major reservoirs of S. aureus
(Charlier et al. 2008). The inflammation directly damages the milk-producing tissue of the
mammary gland. This is a very persistent and widely spread disease among dairy cattle,
which is brought about by many strains of bacteria, yeasts and moulds, however, S. aureus is
responsible for the majority of these cases (Obeso et al. 2008). The severity of the disease in
individual cows varies with the magnitude and duration of the infection. Mastitis, as well as
having a negative impact on the well-being of cattle, is considered to be one of the greatest
causes of economic loss to the dairy industry. This is mostly due to culled cows, discarded
milk, reduced milk quality and the cost of mastitis treatment (Gleeson et al. 2009).

Despite the health risks associated with raw milk, it is still widely consumed as many people
believe that it has a better taste and health benefits. Unsurprisingly, a number of disease
outbreaks have been reported in people following its consumption. Cows are the main source
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of raw milk S. aureus contamination and those with subclinical S. aureus mastitis can shed
large numbers of this pathogen into milk (da Silva et al. 2005). The inflammation associated
with mastitis contributes to decreased milk production and is primarily responsible for the
alterations observed in milk from infected cows. In general, eompositional ehanges involve
an increase in blood components in milk and a decrease in normal milk constituents. Milk is a
complex medium composed of water (typically the major component), lipids, proteins (sueh
as caseins and immumoglobins), lactose (major milk carbohydrate), minerals, vitamins and
milk cells (mostly leukocytes) and non-protein nitrogen (NPN) which is composed of urea
and other low molecular weight compounds such as creatine and creatinine as shown in table

Table 1: The major components of fresh whole fat raw' milk.
Water

86.6 %

Fat

4.4%

Lactose

4.6%

Casein

2.7%

Whey protein

0.6%

NPN

0.1%

Minerals

0.7%

Salts

0.17%

Vitamins and enzymes

0.13%

When secreted into the alveoli of the udder, the milk is sterile and thus, its inoculation must
occur after synthesis (Kelly et al. 2007). S. aureus invades the udder through the teat canal
and colonises secretory cells. This in turn harms the milk producing cells which raises the
somatie eell counts (SCC) in milk. SCC is a useful predietor of subclinical mastitis and
elevated milk SCC is associated with a higher pH of raw milk, altered protein quality, change
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in fatty acid composition, lactose, ion and mineral concentration (Ogola et al. 2009). During
the course of mastitis infection, the number of somatie cells (mostly lymphoeytes) increase
and given that they produce many proteolytic and lipoytic enzymes, have the effeet of
reducing milk quality. They also cause an increase in serum albumin and immunoglobulins in
the milk (Shuster et al. 1997). This increase is possibly due to a disruption to the integrity of
the mammary epithelia by microbial toxins and opening of the tight junetions (Auldist and
Hubble, 1998). Protein breakdown in milk is caused by the heat stable enzyme plasmin. This
is the main caseinolytic enzyme in milk and is nonnally found in milk in small quantities. As
pasteurization cannot inactivate it, milk proteins will continue to be degraded during milk
processing and storage. Leukocytes in the mammary gland produce lipase enzymes in
response to infection and milk fat globule membranes are susceptible to the aetion of these
enzymes. Rancid off-tlavours are a result of lipases breaking down the milk lipids. Milk
quality payments are typically based on SCCs, with elevated levels resulting in less
payments. Cows with higher SCC produce less milk and production losses in older eows are
about double those of first-lactation cows (Schroeder, 1997).

Prev iously, treatment for bacterial mastitis has been limited to the use of broad-speetrum
antibiotics such as penicillin and tetracycline, whieh are often of low effieaey and lead to
milk discard (Oldam and Daley, 1991). Nowadays it is relevant to develop alternative
methods to ensure the hygiene quality of milk. Endolysins possess several features that make
them suitable as potential antibacterials. They are highly specific, have a distinct mode of
action and are active on bacteria regardless of their antibiotic susceptibility pattern (Obeso et
al. 2008). The likelihood of bacteria developing resistance to endolysins is very slim as these
enzymes target highly conserved bonds in the baeterial peptidoglycan. The use of endolysins
to eliminate infections has been well documented in the bovine mammary glands (Kerr et al.
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2001 and Wall et al. 2005).

However little has been done to assess their use for the

biocontrol of pathogens in food. In this study the efficacy of the endolysin CHAPk was
evaluated against the bovine mastitis agent Staphylococcus aureus DPC5246 in various milk
environments, including 10% reconstituted skim, pasteurised and raw milk.
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Materials and Methods

1. Preparation of bacterial growth media
1.1 Brain Heart Infusion broth

37g of BHI broth (Sigma Aldrich) was added to distilled water and made up to 1 litre prior to
sterilization by autoelaving at 121°C for 15 minutes.

1.2 Brain Heart Infusion agar

52 g of BHI agar (Sigma Aldrich) was added to distilled water and made up to 1 litre prior to
sterilization by autoclaving at 121°C for 15 minutes.

1.3 Baird Parker Agar

58g of Baird Parker Agar (Sigma Aldrich) was added to 95()ml distilled water and autoclaved
at 121 °C for 15 minutes. This was allowed to cool to 45-50°C and 50ml egg yolk tellurite
emulsion (Fluka) was added. The agar was mixed thoroughly and dispensed into Petri dishes.
Inoculate the specimen and streak and incubate at 35°C for 24-48 hours.

2. Bacteria and growth conditions.
The strain S. aureus DPC5246 (Dairy Products Research Centre culture eolleetion)
was kept as working culture stoek within the laboratory and had been appropriately stored in
80% glycerol at -20°C. The eells from the glyeerol stock were routinely sub-cultured in BHI
broth at 37°C for 24 hours to maintain viability.
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3. Milk samples.
10% RSM and whole fat pasteurised milk were obtained eommercially. The raw milk was
eolleeted from a dairy fann at Innisearra, Co. Cork between the months of September and
November.

4. Bacterial titre determination by spot plating
Routine titre determination was achieved by spot-plating. Briefly, lOOpl of the culture was
added to 900pl of Ringers solution. This dilution was mixed by pipetting up and down a
number of times, A serial dilution was carried out and lOpl of each dilution was placed as
'spots' in triplicate on an agar plate. The plates were then incubated at 37°C for 24 hours.
After incubation, the number of colonies fonned in each lOpl spot was noted and calculated
to give the number of colony fonning units per ml.

5. Overexpression and purification of CHAPk
CHAPk was heterlogously overexpressed in Escherichia coli XLl-Blue (Agilent
Technologies).Cells were harvested by centrifugation and resuspended in 50mM sodium
acetate pH 6.5.The pellets were lysed by Novagen BugBuster solution (Merck) and the
resulting supernatant was purified by ion-exchange chromatography to high purity using the
AKTAprime automated chromatography system as described in Results (Part 1) of this thesis.
Fractions containing CHAPk were pooled and concentration using Amicon filter tubes
(Millipore). The concentrated enzyme was quantified with the BCA Protein Assay Kit (Pierce
Scientific) and activity determined using turbidity reduction assays.
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6. Activity of CHAPk in 10% RSM,
Staphylococcus aureus DPC5246 was grown overnight in 10% RSM and also in BHI broth
(Sigma Aldrich) as a control. In the morning, milk was titred for S. aureus by spot plating on
Baird Parker agar (Sigma Aldrich) as described above. lOOpl of the required cells at the
required titre were inoculated into 10ml of 10% RSM (l%o inoculation). The spiked milk was
titred a second time for S. aureus by spot plating. The milk was incubated at 37°C. As the
cells had previously been found to enter log phase after four hours, the culture was split in
two after 4.5 hours. To one of the tubes, CHAPk was added at this point (defined as T=4.5).
[Note: The experiment was also carried out with CHAPk being added at TO]. Again milk was
titred for S. aureus by spot plating on Baird Parker agar. Every 15 minutes for one hour after
the CHAPk was added, the cells were titred. Titres were also determined at two-hour
intervals throughout the experiment up to T=8 hours and a final titre at 24 hours was also
taken.

7. Activity of CHAPk in pasteurized milk.
The above experiment was carried out substituting 10% RSM with whole fat pasteurised
milk.

8. Activity of CHAPk in raw milk.
A number of minor differences in methodology were necessary when performing the
experiment in raw milk given that it typically contains a background level of S. aureus. Serial
dilutions of raw milk were carried out in triplicate and spot plated onto Baird Parker agar
(Sigma Aldrich). From these dilutions, the CFU/ml staphylococci in the raw milk as well as
the CFU/ml in an overnight culture could be estimated.
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Overnight culture of S. aureus DPC5246 in milk

Detemiine CFU/ml in the overnight culture and dilute cells to the required titre

1% inoculation into fresh milk and incubate at 3TC

The culture is split into two at T=0 or just before cells reach mid log phase,
Untreated

[—i

"U"

^ With CHAPk added

1

Incubate at 37‘’C

Incubate at 37‘’C

Every 15 minutes tor 1 hour serially

T

Every 15 minutes for 1 hour serially

dilute and spot plate

dilute and spot plate

H

-I-

Continue taking readings every hour and

Continue taking readings every hour and

a final reading after 24 hours

a final reading after 24 hours

Fig 2: Overview' of protocol for determining the activity of CHAPk in milks.
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Results:

CHAPk activity in 10% RSM.

The actively growing bovine mastitis strain S. aureus DPC5246 was inoculated into 10%
RSM. Varying concentrations (50 - 200|ag/ml) of the endolysin CHAPk was added to the
culture half an hour before the cells reached log phase of growth. The experiment was also
performed with addition of CHAPk at T=0.

(a)

1 OOE+08
1 OOE+07
DPC 5246
1.00E+06
1.00E+05
D
LL
O

DPC 5246 + CHAPk
(50|jg/ml)

1 OOE+04

E

DPC 5246 + CHAPk
(100[jg/ml)

1.00E+03

^ DPC 5246 + CHAPk
(150|jg/ml)

m

^ DPC 5246 + CHAPk
(200|jg/ml)

Time (hours)
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(b)

Fig3: Challenge of S. aureus DPC5246 with various eoneentrations of CHAPf^ (ranging from
5()jUg/nil to lOOjug/ml) in J()% RSM. C/lAP/^ was added at (a) T=4.5 and (h) T=(). The X-axis displays
the log CFU/ml of viable eell eounts. The Y-axis shows the time in hours. Error bars represent the
standard errors of nine separate trials.

The activity of CHAPk against the exponentially-growing S. aureus DPC5246 in 10% RSM
was detennined. The inoculation level of the milk was 10^ CFU/ml by the time the enzyme
was added. The addition of CHAPk reduced the viable counts in milk, however at lower
concentrations (50 and lOOpg/ml) the inhibitory effect of the enzyme appeared to have worn
off Bacterial concentrations were determined by serial dilution plating of samples taken
immediately before and after addition of enzyme and at one hour intervals thereafter. The
addition of CHAPk at T=0 was apparently the better approach (compared with adding the
CHAPk at T=4.5 hours). In the case of the two trials, the inoculation level of exponentially
growing S. aureus was x 10^ CFU/ml.

31

Based on the results of the first two experiments, it was determined that the most effective
eoncentration of CHAPk to add to the 10% RSM was 200|Lig/ml. The challenge was repeated
with CHAPk at 20()pg/ml over 24 hours but at a inoculation level of xlO^ CFU/ml.

(a)

■^DPC 5246 in 10%
RSM
DPC 5246 in 10%
RSM + CHAPk
(200ijg/ml)
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(b)

-^DPC 5246 in 10%
RSM
DPC 5246 in 10%
RSM + CHAPk
(200|jg/ml)

Fig 4: Killing of S. aureus DPC5246 in 10% RSM with purified CHAPk (200 pg/nil) over 24 hours.
The first hours are shown in (a) and (h) shows the full 24 hours. S. aureus was at a inoculation level
of xlO^ CFU/ml. The X-axis displays the log CFU/ml of viable cell counts and the Y-axis shows the
time in hours. Error bars represent the standard errors of nine separate trials.

At 20()|.ig/ml, the CHAPk had reduced the levels of S. aureus DPC5246 by five logs after
eight hours (Fig 4a). Titre evaluations after 24 hours (next day) indicated that the S. aureus
had been completely eliminated (Fig 4b).
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CHAPk activity in Pasteurised milk.

The above experiment was also conducted using whole fat pasteurised milk instead of 10%
RSM and CHAPk was added at T=0. Error bars represent standard errors of the means from
at least nine separate experiments.

(a)

-♦—DPC 5246 in pasteurized
milk
-■—DPC 5246 in pasteurized
milk + 200ugyml CHAPk

2

4

6

Time (hours)
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(b)

Fig 5 (a): Activity ofCHAP^ 2()()jug/ml) in pasteurised milk over 8 hours, (h): Activity of
CHAPk (2()()pg/ml) in pasteurised milk over 24 hours. Activity was expressed as Log
CFV/ml.

The activity of CHAPk in pasteurised milk was not high as in 10% RSM. Three hours after
the endolysin was added, the CHAPk activity had reduced and by four hours the numbers of
S. aureus had resumed growth (Fig 5a). After 24 hours there was no difference between the

control and CHAPK-treated milk cultures (Fig 5b).
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CHAPk activity in Raw milk.

The experiment was also perfonned in raw milk. Before spiking the raw milk, the number of
S. aureus naturally present in the milk was determined. To distinguish between indigenous
mierobial flora and the S. aureus DPC5246 (present atlO'^ CFU/ml), Baird Parker agar was
exclusively used for its selective properties.

(a)

-♦— DPC 5246 in raw milk
DPC 5246 in raw milk
+ CHAPk (200|jg/ml)
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(b)

-♦— DPC 5246 in raw milk
DPC 5246 in raw milk
+ CHAPk (200Mg/ml)

(c)

DPC 5246 in raw milk
— DPC 5246 in raw milk
+ CHAPk (250Mg/ml)

Time (hours)

Fig 6: Killing of S. aureus DPC5246 in raw milk with purified CHAPk (200 pg/ml) over 24 hours.
The first hours are shown in (a), the full 24 hours are shown in (h) and (c) shows the aetivity of
CHAPk cit 250pg/ml over 24 hours. The X-axis displays the log CFU/ml of viable eel I eounts and
the Y-axis shows the time in hours. Error bars represent the standard errors of nine separate trials.

37

As shown in Fig 6a and 6b, the CHAPk whilst slightly slowing the growth of the S. aureus,
was not very effective in the raw milk environment at 200ug/ml. Even at higher
concentrations (250ug/ml) the final 24 hour readings showed no difference between the
control and the treated cultures (Fig 6c).As Baird Parker agar was used, the fully grown S.
aureus colonies appeared to be black and shiny. These colonies were typically between 15mm in diameter.
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Discussion

Mastitis not only reduces dairy producer profits but also results in important and costly losses
to processors due to poor-quality milk and a variety of dairy products, including cheeses,
powdered milk and fermented products are affected. The common causes of mastitis are
inadequate milking procedures, milking equipment, long lactations, a high proportion of older
cows, and poor hygiene (Schroeder, 1997). Increased somatic cell counts (SCC) result in
major losses to dairy producers, and elevated SCC level a good indication to the presence of
an intramammary infection (Sharma et al. 2011). Endolysins possess several features that
makes them suitable agents for use as antibacterials such as high specificity and activity
against bacteria regardless of their antibiotic susceptibility pattern (Borysowski et al. 2006).
Another advantage of the use of endolysins is the low probability of bacterial resistance
against these enzymes (Toeftler et al. 2001). Activity in milk or a milk-like environment is an
essential requirement for an anti-mastitis drug administered through the teat canal
(Schmelcher et al. 2012). Bacteriophage endolysins are promising candidates to target S.
aureus in milk. In a previous study by Obeso et al. (2008), the bacteriophage endolysin LysH5 was
shown to inhibit S. aureus growth in pasteurized milk. Purified LysH5 was tested against an
exponentially growing S. aureus Sa9 strain in milk. At a inoculation level of xlO^ CFU/ml, the
addition of 160 U/ml of LysH5 reduced the viable counts to undetectable levels in four hours. At a
inoculation level of 10^ CFU/ml, the addition of 45 U/ml eliminated S. aureus in four hours.

In this study the phage K lysin CHAPk was employed in milk assays as a possible anti
mastitis agent. CHAPk was over expressed in E. coli and purified using ion-exchange
chromatography.

The activity of purified CHAPk was determined in vitro against an

exponentially growing bovine mastitis strain S. aureus DPC5246 in 10% RSM, pasteurized
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milk and raw milk. Initially 10% RSM and pasteurized milk were used to avoid the
complications of having extra fat globules and other bacterial species present in the milk
experiments. The RSM was spiked at two inoculation levels. At a higher inoculation level
(10^ CFU/ml), the addition of CHAPk (50 - 200pg/ml) reduced the viable counts
substantially after one hour, although after four hours the cells had started to resume growth
(Fig 3a). The milk was then treated with enzyme immediately after spiking with DPC 5246
(Fig 3b). This showed a greater reduction in cell numbers compared to the first experiment.
At the lower concentrations of CHAPk (50 - lOOpg/ml) the inhibitory effect of the enzyme
was three and five logs but after 24 hours this inhibition was shown to be only temporary as
the cells had increased their numbers to that of the control. Using CHAPk at 150 and
200pg/ml the CFU/ml of S. aureus after eight hours had dropped by five logs and six logs
respectively. The skimmed milk was spiked with a lower titre of cells (Fig 4a). At this lower
inoculation level the CHAPk when added at a concentration of 200pg/ml worked very well
and even after 24 hours the cells had not resumed growth. One likely explanation for the
regrowth of the S. aureus at higher inoculation levels is that the cell number is too high for
the concentration of enzyme present. Another contributing factor could be changes in the cell
envelope resulting from growth in milk as previously described by Pol et al. (2001). In
addition, S. aureus cells can aggregate and associate with fat globules in raw milk making
them inaccessible to CHAPk. These observations are significant in ternis of applying the
endolysin in milk environments.

Interestingly, a method of improving antibacterial activity in milk has been reported, namely
the use of high hydrostatic pressure (HHP) as described by Tabla et al. (2012). However this
was previously only demonstrated with bacteriophages in milk and not endolysins.
Nevertheless, it may warrant further investigation. Another suggestion for improved lytic
140

activity might be synergy with another antimicrobial agent. Not only would this take
advantage of synergistie effects but it would reduce the likelihood of resistant strain
development (Becker et al. 2008). Also synergy between antimicrobials has been shown
activity even if strains are highly resistant to one of the antimicrobials (Djurkovic et al.
2005).

In conclusion, these results showed that while CHAPk is capable of killing S. aureus in
skimmed milk and pasteurised milk, the outcome of these experiments is dependent on the
levels of S. aureus initial inoculation. Further optimization of the stability of the enzyme is
required for it to have the same effect in pasteurized and raw milk. The most signifieant
finding was that the enzyme does not work well in raw milk.
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Chapter 5

Activity and shelf-life studies on the bacteriophage-derived peptidase
CHAPi
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Abstract
The cysteine/histidine amido hydrolase peptidase (CHAPk) is a single-domain truncated
derivative of the anti-staphylococcal phage endolysin LysK. CHAPk has previously been
characterised in detail at an enzymatic level shown to demonstrate activity against rapidly
dividing Staphylococcus aureus, (Fenton et al. 2011: Characterisation of the staphylococcal
bacteriophage lysin CHAPk- J Appl Microbiol. 111(4):1025-35"). However, certain aspects of
CHAPk characteristics were not reported in the above study, including its activity on aged or
stationary-phase staphylococcal cells and also the effect of freeze-drying on shelf-life. Both
of these properties are investigated in this chapter. The activity of CHAPk on three stationary
phase staphylococcal strains was evaluated over a period of five weeks. In general, cultures
older than three days could be up to 2-fold less sensitive to the endolysin, when aged at 30°C,
although there was less of a difference when cells were aged at 4°C. In addition, the effect of
lyophilization and storage temperature over eight months on CHAPk activity was also
investigated. In general, lyophilization reduced the concentration and activity of the enzyme.
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Introduction

Staphylococcus aureus is a versatile Gram-positive pathogen responsible for a wide speetrum
of diseases in humans and animals with some infections (Somerville et al. 2002). These cells
are non-motile, non-spore fonning facultative anaerobes and grow by aerobic respiration or
by fermentation (Harris et al. 2002). They are characterised by individual cocci, which form
grape-like clusters. The cytoplasm ofS. aureus is protected by a tough cell wall which largely
consists of peptidoglycan (Waldvogel 1990). The bacterial cell wall protects the cell against
fluctuating environmental conditions (Onyango et al. 2012). While staphylococci belong to
the nonnal flora of the mucous membranes and skin, they can quickly become opportunistic
pathogens and are responsible for a wide variety of infections. These infections can be
divided into three types: (a) wound infections, (b) toxinoses such as food poisoning, and toxic
shock syndrome, and (c) systemic and life-threatening conditions such as endocarditis,
pneumonia and meningitis (De Sousa and De Leneastre 2004). As typical for Gram-positive
bacteria, infections are induced through the elaboration of a wide array of extracellular and
cell wall associated proteins (Novick et al. 2000). During the exponential phase, bacterial
metabolism is rapid and efficient to ensure constant growth. As the bacteria age and stop
growing, cellular metabolism is re-organised for long-term survival under unfavourable
conditions (Harris et al. 2002). Bacteria usually enter this stationary phase of growth upon
depletion of nutrients and the accumulation of toxic compounds (Mascio et al. 2007). S.
aureus evolved many mechanisms to overcome environmental stresses by altering the
composition of their cell wall offering increased protection to the cells (Sieradzki and
Tomasz, 1997). This is increasingly important in deep-seated human infections, where
bacterial titres may be as high as 10^ CFU/gram of tissue (Mercier et al. 2002). Despite the
fact that the maximal expression of staphylococcal virulence factors is during the stationary
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phase of growth, the mechanism of action of many antibacterials requires ongoing cell
activity and cell division for any killing activity to occur. Antimicrobials often display limited
activity against non-dividing cultures (Mascio et al. 2007). Bacterial resistance to antibiotics
is usually the result of enzymes that inactivate the antibiotic, reduce membrane permeability,
modify the target protein to a resistant form or produce higher quantities of the target protein
(Donovan and Becker, 2008). Additionally, the reduced susceptibility to antibiotics could be
because of biofdm fonnation. Many cells in a biofilm experience nutrient limitation and
therefore exist in a slow-growing or starved state (Costerton et al. 1999). CHAPk has
previously been shown to demonstrate activity against rapidly dividing Staphylococcus
aureus and while much work has been described regarding the effects of endolysins on
exponential phase cells. In the case of CHAPk, Fenton et al. (2011) has previously defined
the lytic spectrum, optimum pH, temperature, salt concentration, influence of chelating
agents, reducing agents and metal ions on CHAPk and storage of CHAPk in solution at room
temperature. However, much of this work was performed with fresh actively growing cells.
To date, studies have not been performed which explore the efficacy of CHAPk on
stationary-phase cells.

Similarly, no study has been performed looking at the effect of freeze-drying on CHAPk
activity. Freeze-drying, also known as lyophilization, is widely used to improve the stability
and achieve an acceptable shelf life of protein (Tang and Pikal, 2004). It is necessary that
they will remain stable during shipping and over long-term storage (Carpenter et al. 1997).
Lyophilization is carried out using sublimation and consists of two steps: The first is freezing
the protein so that the water in it becomes ice and the second step involves using a vacuum to
sublimate the ice directly into water vapor. This drying step is further divided into two further
parts, which are the primary and secondary drying. The primary drying removes the frozen
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water and the secondary drying removes any lose water (Arakawa et al. 2001).
Lyophilization has been shown to generate a variety of stresses, which depending on the
protein, can bring about various degrees of protein denaturation. These stresses include: (a)
Low temperature, (c) concentration effects, and (c) drying stress (Wang 2000). Due to the
formation of ice crystals lyophilization of proteins rapidly increases the concentration of
solutes and as a result, the protein may be destabilized from changes in its ionic strength and
relative composition. Lyophilized proteins can often loose their activity during storage
(Chang et al. 1993). Thus, in order to be suitable for long term storage, lyophilized proteins
will still need stabilized. The stability of these proteins is greatly influenced by storage
temperature. A solid protein product should be preferable stable at temperatures above O^C
and especially at room temperature. This study detennined the effects of lyophilization and
subsequent exposure to higher temperatures on staphylococcal sensitivity to CHAPk over a
period of eight months.
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Materials and methods

1. Bacteria and growth conditions.
The strains S. aureus DPC5246 (Dairy Products Research Centre culture collection), S.aureus
Newbould 305 (originally isolated from the milk of a cow with mastitis [Prasad and
Newbould, 1968]) and S.aureus Xen 29 (Caliper Lifesciences, UK) were kept as working
culture stock within the laboratory and had been appropriately stored in 80% glycerol at 20°C. The cells from the glycerol stock were routinely sub-cultured at 37°C for 24 hours to
maintain viability.

2. Preparation of stationary-phase bacterial cultures.
Overnight broth cultures of X aureus DPC5246, S.aureus Xen 29 and S.aureus Newbold 305
were grown in BHI broth (Sigma Aldrich) and TS broth (Sigma Aldrich) to generate fresh
liquid cultures. These were grown to mid-exponential phase at 37°C for 24 hours. The
cultures were then incubated at either 4°C or 30 ^’C for 5 weeks. Cultures were checked for
purity, viability and titre, by plating out after the storage period.

3. Bacterial titre determination by spot plating
Routine titre determination was achieved by spot-plating. Briefly, lOOpl of the culture was
added to 900pl of Ringers solution. This dilution was mixed by pipetting up and down a
number of times. A serial dilution was carried out and lOpl of each dilution was placed as
'spots' in triplicate on an agar plate. The plates were then incubated at 37°C for 24 hours.
After incubation, the number of colonies formed in each lOpl spot was noted and calculated
to give the number of colony fonning units per ml.
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4. Overexpression and purification of CHAPk.
CHAPk was heterlogously overexpressed in Escherichia coli XLl-Blue. Cells were harvested
by centrifugation and resuspended in 50mM sodium acetate pH 6.5.The pellets were lysed by
Novagen BugBuster solution (Merck) and the resulting supernatant was purified by ionexchange chromatography

to high purity using the AKTAprime plus automated

chromatography system. Fractions containing CHAPk were pooled and concentration using
Amicon filter tubes (Millipore). The concentrated enzyme was quantified with the BCA
Protein Assay Kit (Pierce Scientific) and activity determined using turbidity reduction assays.

5. Quantification of lysin activity on stationary phase cells.
This was carried out as described in chapter two except with a few modifications. After
incubation, S. aureus DPC5246, S. aureus Xen 29 and S.aureus Newbould 305 were
centrifuged at 400()g for 10 minutes at 4 "C and the pellets were washed twice with 25mM
Tris buffer pH 7.After washing, the pellets were resuspended in 1ml of 25mM Tris buffer pH
7. To ensure that any resistance to the lysin was not due to the high inoculum density of the
cultures, the cells were diluted with buffer until they had the same OD5Q0. lOOpl of the
bacterial suspensions were placed into wells in a 96-well micotitreplate. To each control well
(containing lOOpl of cell suspension) lOOpl of 25mM Tris buffer pH 7 was added. To the test
wells lOOpl of purified lysin in 25mM Tris buffer pH 7 was added At the 15 minute end
point, the lowest concentration/amount of lysin that reduces the OD590 by 50 % compared to
the control wells was noted.
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6. Lyophilization of CHAPk.
The CHAPk endolysin was lyophilised. Eighteen lOpl aliquots of enzyme were placed in
1.5ml centrifuge tubes and kept -SO^'C freezer. When frozen the three tubes at a time were
placed into a 50ml centrifuge tube (standing upright with the cap removed.), which was
inserted into a freeze-drier receptacle (previously washed and cleaned with ethanol). This
process took up to 24 hours. Typically a larger volume was completed in four to five days.

7. Determination of lyophilized CHAPk concentration
The CHAPk concentration was obtained as previously described using the Pierce® BCA
Protein Assay Kit (Themio Scientific). Dilutions of CHAPk required in triplicate were the
neat dilution (25pl of CHAP^), 1/5 dilution and 1/10 dilution. Buffer used was 25mIVI Tris pH
7 (Sigma Aldrich).

8. Quantification of lyophilized lysin activity
Quantification of lyophilized lysin activity was performed as described in Chapter two using

S. aureus DPC5246.
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Results

To evaluate the effect of cell age on CHAPk activity.

In order to determine whether CHAPk had any bacterieidal activity against stationary phase
cells, the three S. aureus strains DPC5246, Newbould 305 and Xen29 were used. Each assay
was carried out in triplicate and included positive controls (cells and buffer) and negative
controls (CHAPk in buffer with no cells). Exponential phase cells of each strain were also
analyzed as a comparison. To identify whether or not storage temperature also mediated
increased or reduced susceptibility to CHAPk, the S.aureus strains were grown for 24 hours
at 37 '’C and then exposed to two different temperatures for five weeks. One half of the
cultures were kept at 4'’C and the other at 30‘'C. None of the cultures were supplemented with
extra fresh media during the trial.

The first series of assays was perfonned using the bovine mastitis strain S.aureus DPC5246.
This stain was previously shown to be very susceptible to CHAPk activity. Activity of the
enzyme against log phase and stationary phase DPC5246 at both temperatures is shown in
Fig 2a. The second strain used was S.aureus Newbould 305 (Fig 2b) shows the overall effect
of cell age and storage temperature on CHAPk when using this strain. The final strain used
was the bioluminescent S.aureus Xen 29. Previous work with Xen29 has shown that it is not
as sensitive to CHAPk as are the other S.aureus strains. Fig 2c shows how the age of Xen29
and its storage temperature affected the concentration of CHAPk needed for cell elimination.
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Fig 1: Representation of the graphs obtained after aetivity assay against S.aureus. The eoneentration
of CHAFi^ required to reduee the
of cultures of S.aureus by half within 15 minutes was taken to
be the MIC. The highest three lines represetil the eontrols eontaining S.aureus and buffer. The lower
three li?ies show the ODyjoof the S.aureus ehallenged against CHAPk

This is a typical example of the graph produced during the activity assay. As 1 unit of activity
has been defined as the amount of lysin that reduces the ODsQoby 50% in 15 minutes (Morgan
et al. 2009), cultures were subjected to lOOpl of increasing concentrations of CHAPk in
buffer until the OD590 of S. aureus was reduced by half within 15 minutes. Assays were
always performed in triplicate.
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(C)

Fig 2: Synopsis of the effect of cell growth phase and temperature of (a) S.aureus DPC5246, (h) S.
aureus Newhould 305 and (e) Xen29 on activity of the endolysin CHAPk. Concentration ofCHAPi^
required to reduce the 00590 of cultures of S.aureus DPC5246 by half within 15 minutes. Pink line
shows the concentrations pertaining to S.aureus, which had been stored at 30‘’C for up to five weeks;
green line refers to concentrations pertaining to S.aureus, which had been stored at 4'’C for up to five
weeks.

For S. aureus DPC5246 (Fig 2a), the concentration of CFIAPk needed to kill fresh
exponential phase cells was 0.5pg/ml. This concentration was found to be equally effective at
killing the cells aged 24 hours to 72 hours regardless of storage temperature. After day seven,
the culture stored at 3()‘’C appeared to become less sensitive to the endolysin with 1.25pg/ml
CHAPk needed to bring about elimination of the cells. The CHAPk concentration required to
kill the cells stored at 4‘'C remained constant over five weeks. In the case of S. aureus
Newbould 305, a similar pattern was observed (Fig 2b). This time however, CHAPk was
needed at an increased concentration after day three at 30”C with 2.5pg/ml needed and after
day seven at 4"C 1.25pg/ml. As was the case with DPC5246 the 30®C culture needed extra
CHAPk in comparison to the 4‘'C culture. Overall, the amounts of enzyme required at either
temperature were not much higher than what was needed for the log phase cells.

For
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S.aureus Xen29 (Fig 2c), the concentration of CHAPk needed to kill fresh exponential phase

cells was 2pg/iTil. For the first three weeks, the culture kept at 30"C was continuously found
to need more lysin compared to the log phase cells with 5pg/ml CHAPk needed to bring
about elimination of the cells. The CHAPk concentration required to kill the cells stored at 4
^’C reached 3pg/ml by day three and remained at this for the rest of the challenge.
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To evaluate the effect of lyophilization and storage temperature on the concentration of
CHAPk.

Lyophilised CHAPk was stored at either 4°C or 21°C for a total of eight months. After one
month, four months and eight months the freeze-dried enzyme was resuspended to lOpl in
sterile water and its protein concentration was determined using the BCA protein assay kit.
An initial concentration assay on the CHAPk before lyophilization was taken.
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Fig 3: (a) Concentnition (fig/ml) of the lyophiHzed CHAFk after storage at 4°C and 2I°C. (h) The %
loss in coneentration ofCIlAPi^ during storage at 4°C and 21°C as eompared with activity of the
original hatch of CHAPk- hhe CHAP/^ stored at 4°C is shown in red and the CHAP/^ stored at 21°C is
shown in purple.

From Fig 3a and Fig 3b, it is evident that while the storage temperate of the lyophiHzed
CHAPk had some effect on protein concentration, the duration of storage had the greatest
influence on concentration. It was found that after only one month, only 73.9% of the original
protein stored at room temperature remained (24.1% loss). However at this stage the CHAPk
kept at 4°C only lost 1% of protein. By month four however, there had been a sharp reduction
in concentration at both 4°C and 21°C with only 41.5% and 28.8% remaining respectively.
After the eighth month, 16.9% of the protein in the 4°C sample and 10.6% of the protein in
21°C sample remained.
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Table I: Summcuy of CHAP concentration and % concentration loss before and after lyophilization.

Storage at 4°C

Storage at 21°C

Storage time

Concentration of
CHAPK(gg/ml)

Percent loss in
concentration

Concentration
ofCHAPK
(pg/ml)

Percent loss in
concentration

Prelyophilization

3250

0

3250

0

One month

3217

1.0

2467

24.1

Four months

1350

58.5

935

71.2

Eight months

550

83.1

935

89.4

Evaluation of the effect of lyophilization and storage temperature on CHAPk activity.

Following the observations on protein loss described above, all batches of CHAPk were
adjusted to the same concentration in preparation for activity assays. Activity is defined in
U/nmol and was detennined using a turbidity reaction assay. Each activity test was performed
in triplicate.
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Fig 4: (a) Activity (V/umol) of the lyophilized CHAP^ to determine the effeet of storage time and
temperature, (b) The % loss in aetivity of CHAP/^ during storage at 4°C and 2I°C as compared with
aetivity of the original hateh of CHAPk- The CHAPstored at 4°C is shown in purple and the CHAPk
stored at 2HC is shown in red.

The activities as defined by activity units are shown in Fig 4a. The dramatic drop in activity
seen after the first month indicates that the act of lyophilization itself appears to have affected
the activity of the enzyme. The storage temperatures of the lysin also contributed to the loss
in activity, especially at 21"C. The percent % loss in activity after lyophillization and storage
for extended periods up to 8 months is given in Fig 5b. By the first month at 4 ‘^C, 80% of the
activity of the enzyme had been lost. The enzyme stored at room temperature saw an even
greater loss of 93.7%. For every four month interval the activity of the enzyme had been
reduced at both temperatures.
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Table 2: Summary of the activity (U/nmol) and % loss in CHAPi^ activity hefore and after
lyophilization.

Storage at 4°C
Storage Time

Storage at 21°C

CHAPk activity

Percent Loss in

CHAPk activity

Percent Loss

units (U/nmol)

activity

units (U/nmol)

in activity

371.7

0

371.7

0

74.34

80

23.23

93.7

37.17

90

18.59

94.9

23.23

93.7

12.39

96.7

Prelyophilization

One month

Four months

Eight months
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Discussion

This study revealed important characteristics of the endolysin CHAPk which has previously
been characterized at an enzymatic level and also shown to be highly active against S. aureus.
To date, studies have not been performed which explore the efficacy of CHAPk on
stationary-phase cells however. Interestingly, related studies have been conducted on
endolysins of Streptococcus pneunomonia, Streptococcus pyrogenes and Bacillus anthracis
with respect to the search of development of lysin-resistant isolates. In these cases, when the
surviving bacteria were treated with lethal doses of lysin, the cells were just as sensitive as
previously. In the case of S. aureus it has been reported that cells became more resistant to
the peptidase lysostaphin after mutation by a transposon insertion (Grundling et al. 2006).
When the peptidoglycan of the mutant cells was purified, structural changes were observed
and this suggested that changes in accessibility of the enzyme to its substrate were likely to
have rendered the bacterium resistant to the lysostaphin.

In situations where staphylococci cause problems in general, the probability exists that a
substantial number of the cells are in the stationary phase such as skin surfaces and various
infections. Furthemiore, it has been reported that slow-growing or non-growing cells are less
sensitive to many currently-used antimicrobial agents (Mercier et al. 2002). During stationary
phase, DNA replication largely is arrested, the number of ribosomes diminishes, and the cell
slows production of the enzymes needed to catalyze the synthesis of the building blocks of
the cell (Mascio et al. 2007). Starving bacteria frequently produce a variety of proteins,
which make the cell much more resistant to damage. These proteins enhance survival by
increasing peptidoglycan cross-linking and thus the cell wall strength. The cells become
harder to kill and less sensitive to environmental changes (Eng et al. 1991).
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Thus the first part of this study challenged CHAPk against stationary-phase broth cultures of
.S aureus DPC5246, S.aureus Xen 29 and S.aureus Newbould 305. All three strains were
maintained in the stationary-phase at temperatures of 4‘’C and 30‘’C for 5 weeks after initial
cultivation at 37''C. Throughout the five weeks, the cultures were not provided with any fresh
nutrients to reduce the number of younger actively dividing cells from developing. Cultures
were challenged with the endolysin after storage for a period of 1, 2, 3, 7, 21 and 35 days.
These cultures were not exposed to CHAPk during storage time. The minimum amount of
endolysin needed to reduce the OD590 of any of the aged cells in 15 minutes was taken to be
the minimum inhibitory concentration (MIC). Prior to lysin challenges, cell batches were
standardized by dilution to an ODs^o of preferably 1.9 (or 0.8 with a plate reader) as
suggested by Morgan et al. (2009).

We observed from day three onwards that the cultures stored at 30 ‘'C typically required in
the region of 2-fold more CHAPk for complete killing. However, after one week incubation
at 4 X the S.aureus DPC5246 did not require a higher concentration of the lysine while
strains Newbould 305 and Xen 29 only required marginally more of the enzyme (typically
1.25-fold more than that required for young cells). Throughout the trial, S.aureus Xen 29
needed higher levels of CHAPk compared to the strains S.aureus DPC5246 and Newbould
305. This is most likely due to strain variation and does not signify development of resistance
to the enzyme. Presently, the only factor, which may contribute to bacterial resistance, is
possible changes in cell wall structure of stationary phase bacteria. Considering, endolysins
and their hosts have evolved over millions of years, any change to the lysin cell wall targets
would take a very long time to occur.
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The second part of this investigation involved evaluating the effect of freeze-drying on the
concentration and activity of CHAPk. Endolysins have promising applications in the food
industry such as dairy and meat (Son et al. 2012). However, when using lysins as a means to
control foodbome contamination, their stability during storage and after application on food
products and in food processing facilities is important (Oliveira et al. 2012). To investigate
the stability, lOpl aliquots of CHAPk was stored at either 4°C or 21°C for a total of eight
months. After intervals of one month, four months and eight months the freeze-dried enzyme
was resuspended in sterile water and was checked for protein concentration and activity.
Previous work carried out by Fenton et al. (2011) had found that when CHAPk was stored in
solution at room temperature, 70% of its activity was lost after two months. In this study, it
was found that the lyophihzed CHAPk continuously decreased in concentration the longer it
was left stored at 4 ‘’C or 21 ‘’C. The concentration of CHAPk decreased steadily over the
eight month period. The majority of protein loss occurred between months four and eight and
as expected, the higher storage temperature gave the greatest protein loss. After the first
month, CHAPk had a reduction in activity. This reduction occurred at both 4 "C (80% loss)
and at room temperature (93.7% loss). Further losses in activity were observed as the months
progressed. After month four, there was a 71.2% loss in protein concentration at 21 "C and a
58.5% loss at 4 ”C. By the eighth month, the lyophihzed CHAPk incubated at 21°C had only
10.6% of it initial activity (total loss of 89.4%) and when stored at 4°C, there was only 16.9%
remaining (total loss of 83.1%). This challenge suggests that as a means of improving shelf
life lyophilization was not successful. It has also been shown that CHAPk is not stable when
stored at temperatures higher than -20 ^’C. As most food and pharmaceuticals would require
storage at higher temperature, further work on improving the stability of the enzyme should
be carried out. This is the first study on endolysin stability.
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In conclusion, CHAPk unlike most antibiotics, is active against both exponential phase and
stationary phase cells and the development of resistanee to this enzyme is very unlikely.
CHAPk represents an alternative novel antibacterial that has rapid lytic activity against
Staphylococcus aureus. In ternis of storage, future work is necessary to allow for CHAPk to
be able to remain stable at higher temperature while in a powder form.
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Conclusion

In recent decades, there has been an increase in the prevalence of antibiotic resistance
among pathogenic bacteria. It has previously been established that bacteriophageencoded endolysins can be used against these antibiotic resistant organisms. These
enzymes are peptidoglycan hydrolases and therefore cause the lysis and subsequent
death of their target bacterial cell. When applied exogenously to Gram-positive
bacteria the lysins can act as exolysins (meaning lysis from outside the cell by an
endolysin) and rapidly bring about cell lysis. Endolysins being peptidoglycan specific
and genus-specific, have a narrow antibacterial spectrum and this makes these
enzymes good candidates to control pathogenic bacteria without disturbing natural
microtlora and also having no apparent detrimental effect on mammalian cells.
Endolysins have two domains, the N-tenninal domain contains the catalytic region of
the lysin and the C-tenninal contains the cell wall binding domain. CHAPk
(Cysteine/Histidine-dependant amidohydrolase peptidase) is a 165 amino acid
truncated derivative of the staphylococcal phageK endolysin, LysK. Throughout this
thesis the bacteriophage K-derived peptidase CHAPk was further characterized.
Parameters for its production were optimised and the resulting CHAPk was evaluated
in vitro for activity against bovine mastitis causing S. aureus. CHAPk was further
evaluated by detennining its sensitivity to lyophilization and its activity on stationaryphase cells.

The standard operating procedures for determining the concentration, activity and
quality of CHAPk were developed in chapter 2. This included the parameters for
culturing, ion-exchange chromatography, desalting, concentration-detemiination and
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activity-detennination. Fifty batches of CHAPk were prepared and from these three
resulting stocks of CHAPk were obtained. Problems with the expression and
purification of the enzyme sometimes occurred, for example, low yield and low
aetivity. In order to get the highest possible yield of enzyme, certain modifications of
the original protoeol for CHAPk produetion were made. By applying these ehanges
better CHAPk yields were achieved and inefficieneies were defined and the improved
methodologies were set out as SOPs. The results of the study were tabulated as they
demonstrate that by implementing these modifications, CHAPk can be effieiently
expressed in a biologically-active foiTn in Escherichi. coli. Not only will this ehapter
be useful for demonstrating the best available methods for CHAPk production, future
workers will be made aware of any issues that may arise and how to deal with them.

Chapter 3 involved eliminating S. aureus from skin using solutions containing either
the CHAPk or the lactic acid and chlorhexidine based teat dip Nanodual. These
antistaphylocoecal agents were evaluated by experimental ehallenge assays on
excised teats and finger skin. As a teat dip, CHAPk reduced the levels of S. aureus by
up to five log eyeles on both animal and human surfaees and the chemical control
Nanodual was found to clear all the eells from both the excised teats and finger skin.
The CHAPk and Nanodual treatments were also evaluated by applying them as a
spray. This was again carried out using excised teats and finger skin. The use of a teat
spray in farms is generally considered to be more efficient as less solution is required,
although it has the disadvantage that it may not cover eaeh teat evenly and pathogens
won’t be fully eliminated. Throughout this study, it was found that applying the lysin
as a spray-on treatment was in fact not as good as dipping. In order to ensure adequate
covering the spray had to be applied twiee, however, overall the same amount of
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solution to dipping was used. On smooth finger skin, the CHAPk spray eaused a three
log CFU/ml reduction in viable cell counts and Nanodual completely eliminated the S.
aureus on the skin. CHAPk was less effective when applied on the teat skin causing
only one log CFU/ml. Nanodual also had poor activity with only a one log reduction
in cell numbers. This strongly indicates that spraying is preventing the treatment from
properly reaching all areas on the teat. As this is more noticeable on the rough skin of
the excised teats, it is probable that the infection is embedded between the grooves of
the skin. The outcome of this investigation is very beneficial as this shows that
CHAPk represents a promising alternative to current teat dips and teat spray. Most of
these treatments are based on harsh chemicals such as chlorhexine, chorine, iodophor
and iodine. As CHAPk is a non-chemical agent, which in contrast to chemicals, would
be less aggressive on skin.

In chapter 4, the efficacy of CHAPk was successfully evaluated against the bovine
mastitis agent S. aureus DPC5246 in various milk environments. The actively
growing S. aureus DPC5246 was inoculated into 10% RSM, pasteurized milk and raw
milk. The main findings were that while CHAPk is capable of killing S. aureus in
skimmed milk and pasteurized milk, the enzyme does not work well in raw milk It
was found that 200pg/ml of the CHAPk was sufficient to eliminate Staphylococcus
aureus in the 10% RSM at two inoculation levels (xlO^ CFU/ml or xlO"^ CFU/ml).
At200|Lig/ml, CHAPk had reduced the levels of S. aureus DPC5246 in the skim milk
by five logs after eight hours and after 24 hours the S. aureus had been completely
eliminated. The activity of CHAPk in pasteurized milk was not as high as with the
10% RSM. Three hours after the endolysin was added, CHAPk had slowed the
growth of the cells however 24 hours after the CHAPk has been added to the culture it
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was found that there was no difference between the control and CHAPK-treated milk
cultures. In raw milk, the CHAPk was even less effective. Concentrations up to
250pg/ml were used but could not sufficiently eliminate the cells. This chapter
highlights the potential of CHAPk to be used against S .aureus in the dairy industry.
Whilst the enzyme may not have been as successful in taw milk, it is possible that
when combined with other methods such as High Hydrostatic Pressure (HHP) or used
with other antibacterials the CHAPk would have a better effect.

Chapter 5 set out to detemiine (a) the level at which CHAPk exhibited bactericidal
activity against stationary-phase cells and (b) if lyophilization had an effect on the
concentration and activity of the endolysin. In situations where staphylococci cause
problems in general, the probability exists that a substantial number of the cells are in
the stationary phase such as skin surfaces and various infections. Furthemiore, it has
been reported that slow-growing or non-growing cells are less sensitive to many
currently-used antimicrobial agents. Exponential phase and stationary phase S .aureus
strains DPC5246, Newbould 305 and Xen 29 were successfully used to further
investigate this. The activity of CHAPk on the three stationary phase staphylococcal
strains was evaluated over a period of five weeks. In general, cultures older than three
days could be up to 2-fold less sensitive to the endolysin, when aged at 30°C,
although there was less of a difference when cells were aged at 4°C. The main
conclusion from this part of study is that while the concentration of CHAPk needed to
be increased to kill stationary phase cells there is still only a low possibility of
resistance development. Thus this endeavour was highly successful. In the second part
of Chapter 5, the effect of freeze-drying on the concentration and activity of the
CHAPk was successfully defined. Lyophilised CHAPk was stored at either 4°C or
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21 °C for a total of eight months. It was found that after the first month, only 67% of
the CHAPk concentration and of 93.7% of its activity remained when stored at room
temperature. The CHAPk kept at 4°C only lost 3% of protein but 80% of activity. By
month 4 however, there had been a sharp reduction in concentration at both 4°C and
21°C with only 42% and 28% remaining reapectively. After the eighth month, 17% of
the protein in the 4°C sample and 11% of the protein in 21°C sample remained. The
majority of activity reduction occured during the first month which indicates that the
act of lyophilization itself appears to have effected the activity of the enzyme. The
storage temperatures of the lysin has also contribed to the loss in activity, especially at
2P’C. This outcomes of this chapter are interesting as the identified areas of concern
with regards to the stability of CHAPk and will undoubtedly be investigated further.

In conclusion, each objective that was set out is this thesis was achieved. Protocols
that allowed optimum production of CHAPk were developed. However, there is also
the opportunity for further work to be carried out, particularly with using CHAPk for
teat dipping and spraying. While it is shown from the results that dipping works better
than spraying, perhaps the teat dip solution may in fact cause the bacteria to bind
more strongly to the teat resulting in fewer bacteria in the Ringers solution and a
lower cell count. Therefore, there is a need to further investigate this. There is also the
opportunity for future work with regards to improving the stability of the enzyme.
During the milk trials, it was found that whilst the activity of the CHAPk is very good
it seemed to decrease rapidly during the course of the trials. It would also be
beneficial to investigate ways to prevent the loss of CHAPk during storage. It has
been found that when stored at temperatures of -20°C and higher, the protein activity
and concentration are affected. If CHAPk could be stored at higher temperatures, it
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could have great potential in the food and dairy industry. Nevertheless, through the
various characterizations and challenges, it was suceessfully shown in this thesis that
CHAPk would be effective as an alternative anti-staphylococeal agent.
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